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in Zusammenarbeit mit dem Universitätsklinikum Gießen und Marburg GmbH,
Standort Marburg
Effect of Ozone/Oxygen-Pneumoperitoneum on
Tumour Growth and Metastatic Spread of the
Rabbit VX2 Head and Neck Cancer Model
Inaugural-Dissertation
zur Erlangung des Doktorgrades der gesamten Humanmedizin
dem Fachbereich Medizin der Philipps-Universität Marburg
vorgelegt von
Ulrich Häußler
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1.1 Head and neck cancer (HNC)
HNC refers to a diverse group of neoplasms, including cancers of the oral cavity, the
pharynx and the larynx. More than 90% of these cancers are squamous cell carci-
nomas (95). Other histologic types are relatively rare and include adenocarcinomas,
adenoid cystic carcinomas, mucoepidermoid carcinomas, lymphomas and sarcomas.
1.1.1 Epidemiology and economics of HNC
Cancer is a major cause of morbidity and death in many countries of the world.
The global cancer statistics reported approximately 10.9 million new cancer cases,
6.7 million cancer-related deaths and 24.6 million persons alive with cancer (within
three years of diagnosis) worldwide in the year 2002 (64). About 6% of all new cases
in 2002 were cancers of the oral cavity, the pharynx and the larynx, accounting for
about 5% of the cancer-related deaths (64).
Age-standardized incidence rates (ASIR) for cancers are used to compare inci-
dences of different regions or countries. The ASIR for cancers of the head and
neck have shown great variance in 2002 between different world areas (64). The
highest ASIR for cancers of the oral cavity and oropharynx were found in western
Europe, southern Europe, south Asia, southern Africa and Australia/New Zealand.
The highest ASIR for cancers of the larynx were found in southern Europe, eastern
Europe, south America and western Asia. Nasopharyngeal cancers are endemic in
some areas of China, southeast Asia, northwest India and northern Africa.
In the United States of America, a total of 559,312 cancer-related deaths were
recorded in the year 2005 (23% of all deaths) (48). Only heart diseases caused more
deaths in the same year (652,091 deaths). In men aged 60 to 79 years and in women
aged 40 to 79 years cancer is the leading cause of death. In the time period from
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1990 to 2004 the age-adjusted cancer death rates have decreased for cancers of the
oral cavity, pharynx and larynx in both genders. Nevertheless, the 5-year relative
survival rate for cancers of the larynx has not improved over the past 25 years in the
United States (48). The American Cancer Society predicts 1.4 million new cancer
cases in the United States of America for the year 2008 (48). Of these 1.4 million
new cancer cases, 35,310 cases (2.5%) are expected to be cancers of the oral cavity
and pharynx and 12,250 cases (0.9%) cancers of the larynx. The incidence in men
is expected to be significantly higher than the incidence in women.
Since HNC is a common disease, the economic impact related to this disease is
of great importance. Lee et al. performed a systematic review of the literature
between 1990 and 2002 adressing the economics of HNC in developed countries of
North America, Europe, Australia and Japan (57). The estimates for the nation’s
annual costs ranged from 1.2 billion Euros in Germany to 1.9 billion Euros in the
United States. Included in these costs were direct as well as indirect costs. The
estimated per-patient lifetime costs associated with the treatment of HNC ranged
from 8,450 Euros in Greek oral cancer patients over 36,871 Euros in Dutch patients
to 231,308 Euros in American lip, oral cavity and pharynx cancer patients. Although
these data have to be interpreted carefully, it is clear that cancers of the head and
neck cause enormous costs to the society.
Therefore, an effective and cheap anticancer therapy would not only be of high
interest to the patient, but also for the global medical care as well as for the financial
situation of state health insurance.
1.1.2 Treatment of HNC
Standard treatment
The standard modalities for the treatment of head and neck squamous cell carci-
nomas (HNSCC) are surgery, radiotherapy and chemotherapy, or combinations of
these. The decision which treatment modality or which combination therapy is
used depends on several factors, including tumour site, tumour stage, comorbidity,
decision of the patient and aimed functional outcome.
Conventionally, surgery or radiotherapy is the treatment of choice for early stage
disease (stages I and II) (95). Both are applied with curative intent. Depending on
the stage and the site of the disease, prophylactic neck treatment or prophylactic
neck dissection can be recommended. Two strategies of altered fractionation radio-
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therapy are applied: hyperfractionation and accelerated fractionation (35). With
both approaches, better local control rates could be achieved compared with stan-
dard fractionation radiotherapy. It is unclear if there is a survival benefit.
In general, the standard treatment of locoregionally advanced disease (stages III,
IVa, IVb) is more complex. The traditional treatment approach for potentially
resectable tumours is surgery with postoperative radiotherapy (95). Newer treat-
ment strategies in the case of potentially resectable tumours add chemotherapy to
surgery and/or radiotherapy (35). Induction chemotherapy with cisplatin and fluo-
rouracil followed by definite radiotherapy was a standard treatment option for local
and regionally advanced cancers of the larynx, with the often achieveable goal of
larynx preservation (35). The fact, that higher rates of larynx preservation could
be achieved with concurrent chemoradiotherapy than with induction chemotherapy
and subsequent radiotherapy, led to the assumption, that concomitant chemoradio-
therapy is probably the best treatment option for locoregionally advanced laryngeal
cancers (35). Concurrent chemoradiotherapy is the treatment of choice for local
and regionally advanced cancers of the oropharynx and for locally advanced and
unresectable tumours (35).
For patients with distant metastatic or recurrent disease, systemic chemotherapy
is the standard treatment modality, applied with palliative intent. It remains unclear
whether chemotherapy prolongs survival. Traditionally, single-agent chemotherapy
was performed, with methotrexate or cisplatin as the most commonly used sin-
gle agents (95). Other active agents are carboplatin, 5-fluorouracil, paclitaxel, do-
cetaxel, doxorubicin and bleomycin. Treatment with combination chemotherapy
resulted in better response rates than single-agent chemotherapy. The combina-
tion of cisplatin and fluorouracil is nowadays regarded as the standard chemother-
apy regimen for metastatic or recurrent disease (35). However, in comparison with
single-agent chemotherapy no improved survival could be shown in multiple studies.
Newer regimens, for example the combination of cisplatin with a taxane (paclitaxel
or docetaxel), are under investigation.
New treatment strategies
A novel approach in therapy of HNSCC is the treatment with epidermal growth
factor receptor (EGFR) antagonists (35). The EGFR is a receptor tyrosine kinase
which was found to be overexpressed in many head and neck cancers. Cetuximab
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is a monoclonal antibody directed against the ligand binding site of the EGFR.
Cetuximab was tested as a single-agent, in combination with radiotherapy and in
combination with cytotoxic chemotherapy. An uncontrolled, multicenter phase II
study enrolling 103 patients evaluated monotherapy with cetuximab in metastatic
platinum-resistant disease (94). Partial response was seen in 13% of patients and
stable disease was found in 33% of patients. A phase III randomized trial compared
cisplatin alone with cisplatin and cetuximab in metastatic/recurrent head and neck
cancer (22). No significant difference in overall survival and progression-free sur-
vival was found between these groups, but the cetuximab and cisplatin combination
group showed significantly improved response rates. Another multicenter European
study showed a significantly increased overall survival for the combination of ce-
tuximab, cisplatin and fluorouracil compared with cisplatin and fluorouracil alone
in patients with metastatic/recurrent disease (93). Cetuximab was also tested for
locoregionally advanced disease in combination with radiotherapy (16). Compared
with radiotherapy alone, progression-free survival and overall survival were signifi-
cantly prolonged. Other anti-EGFR strategies are also under investigation, including
the small molecule tyrosin kinase inhibitors erlotinib and gefitinib.
1.2 The VX2 carcinoma animal model
The VX2 auricle carcinoma is a highly suitable animal model for human HNSCC,
since both are similiar in growth leading to early regional lymph node metastases
and subsequent distant metastatic spread.
1.2.1 History
In a first report in 1932, Shope discussed a tumour-like condition that was found in a
wild cottontail rabbit shot in 1931 (82). These subcutaneous tumours were transmis-
sible to both wild and domestic rabbits. A virus as the papilloma-producing agent
was detected by Shope and Hurst in 1933 (83). A multistep transformation from
benign papilloma to malignant carcinoma was observed in domestic rabbits bearing
the papillomas for more than 4 months (70). The first successful transplantation
of such a carcinoma in Dutch belted rabbits was reported in 1936, but a second
transfer failed (51). Successful transplantation of the squamous cell carcinomas in
Dutch belted rabbits with increasing take-rates, increasing anaplasia and frequent
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occurence of metastases until the 14th generation was reported in 1940 (52). This
transplantable squamous cell carcinoma was called Carcinoma V2, while the name
Carcinoma V1 was given to the previous cancer that was lost after the first successful
transplantation. After World War II, the carcinoma was renamed Carcinoma VX2,
due to the other meaning that V2 achieved during the war (71). During propagation
to the 47th generation, the tumour had lost the power to immunize the host against
the Shope papilloma virus, thus the Shope papilloma virus probably got lost during
propagation (71). Heterologous transplantation to the brains of guinea pigs, ham-
sters, rats and mice and to the subcutaneous space of hamsters and mice succeeded
(37).
Nowadays, the VX2 carcinoma is a well established and often used in vivo tumour
model, which can be transplanted to a variety of anatomical sites in the rabbit.
1.2.2 The VX2 auricle carcinoma
The VX2 auricle carcinoma of the New Zealand White (NZW) rabbit is applied as an
animal model for HNC in humans and was originally designed by van Es et al. (90).
The tumour take-rate (with freshly prepared tumour cell suspensions) varies from
78% (89) to 99% - 100% (75; 32). One characteristic feature of the VX2 auricle
carcinoma is that metastatic spread primarily occurs to the first draining lymph
node and remains limited to the first draining lymph node for some time (sentinel
lymph node) (32). Later, after breakdown of the physiologic integrity of the sentinel
lymph node, further lymphogenic metastatic spread to a secondary lymph node
station and finally haematogeneous metastatic spread to the lungs occurs. Dünne
et al. investigated the lymphogenic metastatic spread (31; 32). About two weeks
after the tumour induction, a high percentage of animals has lymph node metastases
in the first draining lymph node (62.5% on day 14 (31) and 100% on day 18 (32)),
but metastases to the second draining lymph node station do not occur until day
28 after tumour induction. In the course of the disease, lung metastases frequently
occur. Van Es et al. found lung metastases in 47% of animals that were sacrificed
at different time points more than 28 days after tumour induction (89).
Since 1999, the VX2 auricle cancer model was used in some experimental studies:
 intraarterial tumour embolisation studies, with assessment of the use of Dex-
tran hydrogel microspheres for tumour chemo-embolisation and the use of




 an immunotherapy study with local (peri-tumoural) interleukin-2 (IL-2) ap-
plication (88)
 a systemic chemotherapy study with special regard to the metastatic lymph
nodes, using intravenous applied cisplatin as the chemotherapeutic agent (30)
 a study investigating the effect of bipolar radiofrequency thermotherapy on
lymph node metastases (33)
 a surgical intervention study comparing piecemeal laser resection with en bloc
cold steel resection (75)
 a study evaluating the effect of translymphatic chemotherapy with cisplatin
on lymph node metastases (29).
1.3 Ozone
1.3.1 Overview
Ozone is a triatomic molecule, composed of three oxygen atoms forming a cyclic
structure. Martinus van Marum, a Dutch chemist, in 1785 first noticed the devel-
opment of a distinct odour when using his electricity machine, named the “odour
of electricity” (72). Christian Friedrich Schönbein, a German Professor of Chem-
istry at the University of Basel (Switzerland), in 1840 made the suggestion that
this odour is caused by a distinct chemical substance and he proposed the name
ozone for this substance, derived from the Greek word “ozein” (smell). The cor-
rect molecular formula of ozone, O3, was discovered by Jacques-Louis Soret in 1865
(72). In the atmosphere, ozone reaches the highest concentration in the stratosphere
(ozone layer), where it is produced continually when ultraviolet radiation reacts with
oxygen, a process known as the ozone-oxygen cycle. Thus, B and C ultraviolet ra-
diation, known to be dangerous for humans when entering the troposphere in high
concentrations, is absorbed in the stratosphere. On the other hand, tropospheric
ozone, as it occurs in photochemical smog, is mainly regarded as a pollutant having
harmful effects on human health.
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Ozone is a highly reactive oxidant gas, that reacts immediately when it comes
in contact with biomolecules. The primary target molecules for ozone in biologi-
cal systems are unsaturated fatty acids (UFA), antioxidants like ascorbic and uric
acid, thiol compounds like the amino acid cysteine, reduced glutathion (GSH), al-
bumin, carbohydrates, enzymes, DNA and RNA (15). In the presence of water,
the reaction of ozone with polyunsaturated fatty acids (PUFA) leads to the forma-
tion of hydrogen peroxide (H2O2) and lipid ozonation products (LOPs), which are
regarded as important messengers mediating toxic as well as therapeutic effects of
ozone in the human body (68; 15). Interestingly, ozone was recently found to be
produced antibody-catalyzed in human neutrophils and therefore itself is considered
a biomolecule (5).
1.3.2 Ozone and cancer
Toxicity and possible carcinogenicity of ozone
Research on the biological effects of ozone inhalation has predominantly been focused
on pulmonary toxicity. In animal experiments, inhalation of ozone caused pulmonary
inflammation, pulmonary oedema and epithelial cell damage in a concentration-
dependent manner (55). Chronic exposure to elevated ambient ozone concentrations
caused sustained bronchiolitis and the development of lung fibrosis in animal studies
(55).
Much interest has been directed towards a possible carcinogenic effect of chronic
exposure to elevated ambient ozone concentrations. The potential carcinogenicity of
ozone has been studied in experimental animals. Some experiments using strain A/J
mice provided evidence that chronic ozone exposure increases lung tumour devel-
opment in mice (42; 56). In contrast, these results were not reproducible in a later
experiment (98). Furthermore, chronic ozone exposure did not cause an increase of
lung tumour development in Swiss Webster mice (56). The largest study on this
topic was conducted by the United States National Toxicology Program (1). No
evidence of a carcinogenic activity of chronic ozone exposure was found in male and
female F344/N rats. On the other hand, the incidence of alveolar/bronchiolar ade-
noma was significantly increased in female B6C3F1 mice and was slightly increased
in male B6C3F1 mice. Fewer studies exist which explore a possible carcinogenic
effect of ozone in humans. The Adventist health study on Smog among Californian
adults showed an increase in the incidence of lung cancers with elevated long-term
7
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ambient concentrations of O3 in men, but not in women (7).
Possible antitumoural effects of ozone
Interestingly, other reports suggest a possible antitumoural effect of ozone. Early
research papers described ozone as a possible radiomimetic gas, leading to the devel-
opment of distant signs (for example a sphering tendency of circulating erythrocytes)
after inhalation in animals and men (19; 20). These distant signs were comparable
to those seen after exposure to ionizing radiation. These observations inspired re-
searchers to test, if ozone effects on cancer cells are comparable to those of ionizing
radiation and if ionizing radiation and ozone can have an additive effect on cancer
cells.
Comparing the effect on mouse ascites tumour cells in aqueous suspension, Sach-
senmaier et al. only found small similarity between ozone and X-rays (73). There is
some evidence from further in vitro studies, that exposure to ozonated air can selec-
tively inhibit the proliferation of human cancer cells (lung adenocarcinoma, breast
adenocarcinoma, uterine carcinosarcoma and endometrial carcinoma) at ozone con-
centrations that do not cause growth inhibition of human fibroblasts (87). The
observation that growth inhibition of human cancer cells in vitro (endometrial can-
cer) after irradiation with a gamma emitter could be increased when the cancer cells
were preincubated with an O3/O2 gas mixture, led to the proposal that ozone may
have radiosensitizing properties (50).
Controlled randomized clinical trials that demonstrate a clear antitumoural ef-
fect of ozone therapy in human cancer patients do not exist. Two pilot studies
by Clavo et al. which evaluated systemic ozone therapy for human cancer had en-
couraging results (26; 25). The method employed in these studies was the major
autohaemotherapy, which will be described later. In the first study, they found that
ozone therapy increased oxygenation in the most hypoxic metastatic lymph nodes in
patients with advanced head and neck cancers (25). Regarding the fact that tumour
hypoxia is a major cause of radioresistance, increased tumour oxygenation could be
helpful to overcome radioresistance. In the second study, they compared the effect
of ozone therapy and concurrent radiotherapy with chemoradiotherapy in patients
with unresectable, locoregionally advanced and in some patients distant metastatic
head and neck cancers (26). Despite the fact that the patients in the ozone therapy
group were significantly older and had more advanced disease stages, the median
8
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overall survival in both groups was not significantly different. There was even a
tendency towards a longer median overall survival in the group which received the
ozone therapy concurrently to the radiotherapy (8 months versus 6 months). These
results implicate a possible additive effect of the ozone therapy in human patients
with advanced cancer.
1.3.3 Ozone therapy today
Routes of ozone application and indications for ozone therapy
Several routes of ozone application have been described so far (15; 74). Ozone
can be applicated topically to external body surfaces (for example poorly healing
wounds). For topical application ozonated oils are available too (78). Another
principle of ozone application is insufflation via naturally existing body orifices, for
example rectal, urethral, vaginal, auricular and nasal insufflation. Subcutaneous,
intramuscular, intralesional and periarticular injection of ozone is possible as well.
A further principle of ozone application is injection into preformed body cavities,
for example intrapleural, intraarticular and intraperitoneal application, which was
used in this study (59). The most commonly used method is the so called major
autohaemotherapy (major AHT). A certain volume of fresh drawn blood is exposed
to an equal volume of an O3/O2 gas mixture with a definite ozone concentration
ex vivo and is afterwards reinfused intravenously (15). In minor autohaemotherapy
(minor AHT) a much smaller blood volume is exposed ex vivo to an equal volume
of an O3/O2 gas mixture with a higher ozone concentration than used in the major
AHT, and the mixture is then injected intramuscularly into the gluteus muscle (15).
Only of historical interest is the direct intravenous or intraarterial injection of an
O3/O2 gas mixture. Due to the risk of pulmonary embolia, this technique was
prohibited in Germany in 1984.
Indications for ozone therapy according to the German Medical Society for the
Use of Ozone in Prevention and Therapy are summarized in Table 1.1 (6).
Ozone therapy and orthodox medicine
The therapeutical application of ozone is still a subject of controversy. In Germany,
the G-BA (“Gemeinsamer Bundesausschuss der Ärzte und Krankenkassen”), which
is formed by the national associations of doctors and dentists, the German Hospital
9
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Table 1.1 – Indications for ozone therapy according to the German Medical
Society for the Use of Ozone in Prevention and Therapy
Major AHT Rectal Insufflation
- peripheral arterial circulatory disturbance - ulcerous colitis
- cerebral circulatory disturbances (stroke, TIA) - proctitis, stages I and II
- ocular circulatory disturbances (retinopathies) - anal fistulae and fissures
- acute hearing loss, tinnitus
- virus-caused disease (herpes simplex) Minor AHT
- immune deficiency or weakness - acne vulgaris
- complementary therapy in geriatric and - allergies
environmental medicine and oncology - as an adjuvant in cancer therapy
- immunoactivation in sports medicine
Topical application
- external ulcers, skin lesions Intraarticular injection
- burns, superinfected - rheumatic diseases
- local infections - active gonarthrosis, shoulder stifness





Federation and the federal associations of health insurance funds, is responsible for
the assessment of new methods of medical diagnosis and treatment. In a statement
of the G-BA published in the year 2001, ozone therapy was rejected for all indications
with the rationale that benefit, necessity and economic efficiency of ozone therapy
are not sufficiently documented (21). For supporters of ozone therapy, a lack of
solid scientific data, excessive empiricism, ozone toxicity, the use of ozone therapy
by charlatans and a disinterest of health authorities are possible reasons why ozone
therapy has not been accepted by orthodox medicine, yet (15).
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2 Study objective
As described above, there is a lack of high quality animal and human studies eval-
uating ozone therapy for cancer treatment. The selective inhibition of the growth
of human cancer cells in vitro, the encouraging results in human pilot studies and
the proposed immune-modulatory effect of ozone, point interest on ozone as a pos-
sible therapeutic agent for cancer treatment. This study was performed to test
the hypothesis that intraperitoneal application of a medical O3/O2 gas mixture
(O3/O2-Pneumoperitoneum, O3/O2-PP) is an effective antitumour approach. In-
traperitoneal application of the O3/O2 gas mixture was chosen because with this
method, in comparison to the method of major autoheamotherapy, a high gas vol-
ume could be applicated. The VX2 auricle carcinoma in NZW rabbits is a very
reliable animal model for evaluation of intraperitoneal O3/O2 gas therapy, because
the tumour is aggressive, easy accessible and the routes of metastatic dissemination
are clearly delineated.
The O3/O2-PP method was evaluated for:
 overall survival of the rabbits
 effect on the growth of the primary auricular tumour
 effect on the development of regional and distant metastases
 adverse effects and safety
11
3 Material and methods
3.1 Animals and study protocol
The Animal Use Protocol (AUP) was approved by the Regierungspräsidium Giessen
(government of Giessen), Germany, protocol number V 54-19 c 20-15(1) MR, No.
24/2005. This study was performed in accordance with the guidelines of the Decla-
ration of Helsinki and the guidelines of FELASA.
Adult, male Iffa Credo NZW outbreed rabbits (specific-pathogen free) were pur-
chased from Charles River WIGA GmbH (Sulzfeld, Germany). In total, 61 rabbits
weighing 2.0 to 3.0 kg were included in this study. All animals were kept in rooms
with standardized air conditioning at 20-22°C, 50-60% humidity and a 12 hr ar-
tificial day/night rhythm. Each rabbit was held in an individual steel cage, was
fed with 100 g complete diet food pellets per day and had free access to acidified
(hydrochloride acid, pH 2.7) tap water ad libitum. Animals could acclimatize for at
least five days before the experimental procedure was started.
The study protocol is schematically presented in Figure 3.1. The purpose of this
study was to test the effects of the intraperitoneal application of a medical O3/O2
gas mixture (O3/O2-PP) on tumour development and metastatic spread of the VX2
auricle carcinoma in NZW rabbits. The VX2 auricle carcinoma model is a highly
suitable tumour model for human HNSCC (89). A VX2 tumour cell suspension was
inoculated subcutaneously into the right auricle of 48 rabbits (day 0). Success of
transplantation and tumour growth were monitored daily. Additionally, the body
weight was measured daily and the draining lymph node stations of the auricle
were palpated. On day 14 after tumour cell inoculation, the rabbits were randomly
divided into three experimental groups (group A, group B, group C). Rabbits in
group A received an intraperitoneal O3/O2 gas mixture therapy, rabbits in group
B received an intraperitoneal O2 gas therapy, rabbits in group C received a sham
treatment. O3/O2 therapy, O2 therapy or sham treatment were performed daily for
five consecutive days, beginning on day 14 after tumour cell inoculation and ending
12
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on day 18 after tumour cell inoculation. Thereafter, all animals were observed at
regular intervals until day 90 after tumour cell inoculation. Observation included
inspection with special regard to the macroscopic aspect of the primary tumour
and to signs of animal distress, measurement of the body weight, measurement of
the size of the primary auricular tumour, palpation and, if possible, measurement
of the size of the draining regional lymph nodes. If severe infection (indicated by
swelling, smelling, fever) or massive bleeding of the auricular tumour was observed,
ear ablation was performed 1-2 cm proximal to the tumour margin to prevent animals
from early death. After ablation of the tumour-bearing part of the ear, animals
were observed as described above. If the animals showed signs of distress, pain or
cachexia - defined as rapid or consistent body weight loss exceeding 15-20% of the
maximal body weight of the animal - they were sacrificed as is recommended by the
Canadian Council on Animal Care (2). On day 90 after inoculation of the tumour
cell suspension the remaining tumour-bearing animals were sacrificed. All sacrificed
animals were immediately dissected. Rabbits that were macroscopically tumour-
free on day 90 after the tumour cell inoculation and exhibited no enlarged draining
lymph nodes and no lung metastases, as determined by palpation and a computed
tomography scan of the thorax, were defined as cured and included in a consecutive
Figure 3.1 – Study protocol of the main study.
The VX2 tumour cell suspension was inoculated subcutaneously into the right auricle of
48 NZW rabbits on day 0 of the experiment and tumour growth was allowed for 14 days.
On day 14 after the inoculation the rabbits were randomly divided into three experimental
groups: A, B and C. Rabbits in group A received an intraperitoneal O3/O2 gas mixture
therapy (O3/O2-PP), rabbits in group B received an intraperitoneal O2 gas therapy, rabbits
in group C received a sham treatment. O3/O2 therapy, O2 therapy or sham treatment were
performed daily for five consecutive days, beginning on day 14 after tumour cell inoculation





In this consecutive study, the six rabbits of the O3/O2 gas mixture therapy group
with complete remission of the auricular tumour were randomly divided into two
groups. One group was immune suppressed (n = 3) and the other group was sham-
treated (n = 3). The tumour cell suspension was (re-)inoculated into both auricles
of all animals and the tumour (re-)take-rate was evaluated on day 14 after the
(re-)inoculation.
Thirteen rabbits were used as donors, in which VX2 tumour cells were propagated
by intramuscular passage.
3.2 Induction of the VX2 carcinoma
3.2.1 VX2 tumour cell suspension
The in vivo VX2 tumour was used previously for several studies in the Department
of Otolaryngology, Head and Neck surgery, University Hospital Giessen and Mar-
burg, Campus Marburg, Marburg, Germany, and was originally provided by Prof.
Dr. Robert J.J. van Es (Department of Oral and Maxillofacial Surgery, University
Medical Center Utrecht, Utrecht, The Netherlands) (60; 30; 89).
The tumour cells were propagated in vivo by inoculation of a tumour cell suspen-
sion (as will be described below) into one or both upper hind limbs of altogether 13
NZW rabbits. On day 14 after inoculation of the tumour cell suspension into the
hind limbs, the animals were sacrificed and the grown solid tumour was dissected,
removed and cooled on dry ice. Necrotic tissue was removed and the tumour mass
was cut with a scalpel into several small pieces. These were further fragmented with
a razor blade. The resulting foamy mush was pressed through a nylon sieve (mesh
size 300 µm) and collected in cooled Dulbecco’s Modified Eagle Medium (DMEM,
Biochrom AG, Berlin, Germany). The tumour cell and DMEM mixture was cen-
trifuged twice. The thin fluid supernatant was removed and the remaining tumour
cells were suspended with little DMEM, resulting in a viscous suspension. The num-
ber of cells in suspension was counted using a haemocytometer (Improved Neubauer
Ruling). Viability of cells was estimated by the Trypan blue exclusion method. The
suspension was standardized at a mean density of 3-6 x 107 cells/ml and inoculated
into the experimental rabbits and further donor rabbits within less than two hours.
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3.2.2 Tumour cell inoculation
For tumour cell inoculation into the right auricle rabbits were sedated with 5 mg/kg
body weight of the alpha2-agonist xylazine (Rompun®, Bayer Vital, Leverkusen,
Germany), injected intramuscularly into one hind limb. Experience showed that
previous sedation facilitated the handling of nervous animals, reducing physical
stress to the animal and resulting in better standardization of the injected suspension
volume and thus, the resulting tumours.
To induce tumours, 0.3 ml of the tumour cell suspension, containing 1-2 x 107 vi-
tal tumour cells, were slowly injected subcutaneously with a 24G needle (Microlance
3, Becton Dickinson Medical Systems, Drogheda, Ireland, outer diameter 0.5 mm).
Prior to the tumour cell suspension inoculation, a small amount of air was injected
subcutaneously to produce a small subcutaneuos pouch, which made it easier to
inoculate the tumour cell suspension. Tumours were transplanted between the cen-
tral auricular artery and the caudal margin at the dorsal middle-third of the right
auricle. Sometimes regurgitation of the tumour cell suspension occured, but the
volume was very small and thus negligible.
3.3 Monitoring, blood withdrawal and photo
documentation
3.3.1 Overview
Prior to encasement of the rabbits in this study, their general health condition was
assessed by an experienced veterinarian. On day 0, prior to inoculation of the
tumour cell suspension into the right auricle, the body weight and the basal body
temperature were measured and an arterial blood sample was drawn from the central
auricular artery of the left auricle. The sites of the draining lymph nodes (parotideal,
submandibular, cervical) were located by palpation to rule out any enlarged lymph
nodes before the tumour induction was performed.
The routine monitoring procedure consisted of:
 inspection with special regard to the macroscopic aspect of the primary tu-




 measurement of the body weight
 measurement of the primary auricular tumour in three dimensions (the largest
diameter, one diameter perpendicular to the largest diameter and the complete
thickness including the underlying auricle)
 palpation and, if possible, measurement of the parotid lymph node in one
dimension (the largest diameter)
 the basal body temperature was measured in addition, if the primary tumour
seemed to be infected or if the animal showed signs of distress.
In the time period from day 1 to day 19 this routine monitoring was done daily.
In the time period from day 20 to day 90 this monitoring procedure was performed
at least every second day. On day 14, prior to the first therapeutic session, and on
day 19, 24 hours after the last therapeutic session, blood was taken from the central
auricular artery of the left ear. The last arterial blood sample was taken on day 90
or on the day at which the animal was sacrificed.
3.3.2 Measurement of body weight, body temperature, tumour
and lymph node size
The body weight was recorded with a Multina Plus baby scale (Soehnle Professional
GmbH and Co. KG, Murrhardt, Germany) with “weight-lock-function”, that allows
precise measurements with an accuracy of 0.01 kg even if the rabbit is agitated. The
rectal body temperature was measured with a digital thermometer with an accuracy
of 0.1°C. The size of the primary ear tumour and the largest diameter of the parotid
lymph node were measured with a digital calliper (S Cal Work, Sylvac SA, Chrissier,
Switzerland).
3.3.3 Blood withdrawal and blood parameters
Blood was taken from the central auricular artery of the left tumour-free ear. For
the puncture, a 19G needle (Microlance 3, Becton Dickinson Medical Systems,
Drogheda, Ireland, outer diameter 1.1 mm) was used.
EDTA whole blood samples were collected for haematological investigations with
an autoanalyzer (Vet abcTM Animal blood counter, ABX Diagnostics, Goettingen,
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Germany) that has been carefully adjusted and validated for the analysis of rab-
bit blood. The following parameters were determined by the autoanalyzer: to-
tal white blood cells (WBC) which were further differentiated into granulocytes
(GRA), monocytes (MO) and lymphocytes (LYM); total red blood cells (RBC),
haemoglobin (HGB) and haematocrit (HCT). Clinical chemistry investigations were
done with a reflexion photometer (Reflovet® Plus, Roche Diagnostics, Mannheim,
Germany). The following parameters were determined: creatinine (CREA), serum
glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic transam-
inase (SGOT). The following blood samples were used: CREA - EDTA whole blood,
SGOT/SGPT - heparin plasma. For arterial blood gas analysis a blood gas analyzer
was used (ABL 500, Radiometer, Copenhagen, Denmark). The following parameters
were measured: pH, pO2 and pCO2.
3.3.4 Photo documentation
A digital single-lens reflex camera model (Nikon D70, Nikon GmbH, Duesseldorf,
Germany) was used for photo documentation. Photos of the tumour-bearing right
auricle were taken on day 14 and then once a week up to day 90. The photos were
edited with the Adobe Photoshop® CS program (Adobe Systems GmbH, Munich,
Germany).
3.4 O3/O2 gas mixture therapy, O2 gas therapy and
sham treatment
3.4.1 O3/O2 gas mixture therapy (O3/O2-PP)
The O3/O2 gas mixture therapy was performed daily for five consecutive days (Fig-
ure 3.1). A short-lasting anaesthesia was given each day to sufficiently immobilize
the rabbit during the short period of intraperitoneal O3/O2 gas mixture insufflations.
Rabbits were premedicated with 0.02 mg/kg body weight glycopyrrolate (Robinul®,
Riemser Arzneimittel AG, Greifswald, Germany) injected subcutaneously, followed
by intramuscular application of 0.3 mg/kg body weight medetomidine hydrochlo-
ride (Domitor®, Pfizer, Karlsruhe, Germany) plus 3-6 mg/kg body weight propo-
fol (Propofol 1% Fresenius, Fresenius Kabi Deutschland, Germany) injected intra-
venously. After the treatment anaesthesia was finished by intravenous injection of
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the medetomidine reversal agent atipamezole hydrochloride (Antisedan®, Pfizer,
Karlsruhe, Germany), 1.5 mg/kg body weight.
For generation and intraperitoneal insufflation of the medical O3/O2 gas mixture
the MedozonIP gas processor (Herrmann Apparatebau, Kleinwallstadt, Germany;
certified ISO 13485:2003 Nr. Q1N 06 10 51287 005) was used (Figure 3.2). The gas
mixture, which was generated from pure medical oxygen, was composed of 97.5%
O2 and 2.5% O3. A standardized gas volume of 80 ml/kg body weight with a
concentration of 50 µg O3/ml gas was insufflated each day. This is an empirical dose
with a medium concentration of ozone based on early observations in veterinary trials
by Dr. S. Schulz (Veterinary Service and Laboratory Animal Medicine, Philipps
University Marburg, Germany) (4).
The top of a 17G Vasofix® Braunuele® (Braun Melsungen AG, Melsungen, Ger-
many) was carefully implanted into the right lower quadrant of the abdomen. There-
after 2 ml of a sterile NaCl solution were slowly injected into the abdomen to control
the correct intraperitoneal position of the Braunuele®. The end of the Braunuele®
was connected to the Medozon IP gas processor via a sterile Ozon-Kit (Ozone-Set
ip REF HAB no. 18052, Herrmann Apparatebau, Kleinwallstadt, Germany). Begin-
ning at the side where it is connected to the gas processor the Ozon-Kit consists of
a sterile filter, followed by a plastic tube of 150 mm length with a stopcock where it
is connected to the Braunuele®. The MedozonIP gas processor has a special device
to which the Ozon-Kit can be connected for removing the air from the plastic tube
and refilling it with the recommended gas. To prevent inappropriate high abdominal
pressure, the MedozonIP gas processor has an integrated intraabdominal pressure
control system (IAPC), which stops insufflation automatically when the measured
intraabdominal pressure raises to a threshold value. During the insufflation process,
the actually insufflated gas volume, the adjusted ozone concentration and the cur-
rent intraabdominal pressure are presented on the monitor of the MedozonIP gas
processor. At the end of the insufflation process the Braunuele® was removed from
the abdomen. In total, the rabbits received 400 ml/kg body weight of the O3/O2
gas mixture with an ozone concentration of 50 µg/ml over the five days.
3.4.2 O2 gas therapy
The O2 gas therapy was performed daily for five consecutive days. The animals
were anaesthetized the same way as the animals in the O3/O2 group. For insuffla-
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Figure 3.2 – Equipment for gas insufflations.
Picture A was made during the treatment process. A Braunuele® (Braun Melsungen
AG, Melsungen, Germany) is implanted into the right lower abdominal quadrant of an
anaesthetized rabbit. This Braunuele® is connected to a MedozonIP gas processor (Her-
rmann Apparatebau, Kleinwallstadt, Germany) via a sterile Ozon-Kit (Ozone-Set ip REF
HAB no. 18052, Herrmann Apparatebau, Kleinwallstadt, Germany). Picture B shows the
Braunuele®connected to the Ozon-Kit which at that side consists of a plastic tube and a
stopcock. Picture C shows the MedozonIP gas processor and the other end of the Ozon-Kit
with the sterile filter.
tion of pure oxygen the same MedozonIP gas processor was used. A standardized gas
volume of 80 ml/kg body weight of pure medical oxygen was insufflated intraperi-
toneally each time, resulting in an insufflated volume of 400 ml/kg body weight of
pure medical oxygen over the five days.
3.4.3 Sham treatment
In the sham treatment group animals were anaesthetized as described above. A 17G
Braunuele® was implanted into the abdominal cavity and connected via the Ozon-




As mentioned above, to prevent animals from early death an ear ablation was per-
formed. Ear ablation was indicated when massive bleeding of the primary tumour
occured or when redness, swelling and smelling of the tumour-bearing auricle com-
bined with increased body temperature strongly suggested severe infection of the
primary tumour and the underlying auricle.
Animals were premedicated with 0.02 mg/kg body weight glycopyrrolate (Robinul®,
Riemser Arzneimittel AG, Greifswald, Germany) injected subcutaneously. General
anaesthesia was given with 5 mg/kg body weight xylazine (Rompun®, Bayer Vi-
tal, Leverkusen, Germany) and 70 mg/kg body weight ketamine (Ketavet®, Pfizer,
Karlsruhe, Germany), both injected intramuscularly. In some cases up to 10 mg/kg
pentobarbital (Narcoren®, Merial GmbH, Hallbergmoos, Germany) were addition-
ally injected intravenously.
The resection line was placed 1-2 cm proximal to the tumour margin. The hair in
this region was shaved and the skin was disinfected with Braunol®(Braun Melsungen
AG, Melsungen, Germany). First, the central auricular artery was ligated proximal
to the resection line. For resection a disposable scalpel was used. A 2-3 mm wide
stripe of the cartilage along the resection line was additionally resected. Now the
overlaying skin on both sides of the cartilage could easily be pulled and sutured
together (2/0 Serapid, EP 3, Serag-Wiessner KG, Naila, Germany) with continuous
suture. The sutures were removed on the 7th to 10th postoperative day.
The resected tumour was measured in three dimensions, as described above. For
microbiological testing a smear was taken from the necrotic parts of the tumour
and transferred into a Port-A-CulTM Tube (Becton Dickinson Medical Systems,
Drogheda, Ireland) for transport. The microbial analysis was done by the Insti-
tute of Microbiology, University Hospital Giessen and Marburg, Campus Marburg,
Marburg, Germany.
3.6 Sacrifice and dissection
3.6.1 Sacrifice
Endpoint criteria were defined according to the Canadian Council on Animal Care
and the UK Co-ordinating Committee on Cancer Research (UKCCCR) (2; 3)
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These endpoint criteria were:
 rapid or consistent body weight loss exceeding 15-20% of the maximal body
weight of the animal
 interference with normal body functions due to the mass of tumour tissue
at different locations (parotid lymph node enlargement - interference with
chewing and eating; lung metastases - dyspnoe accompanied by cyanosis)
 somnolence and all further steps in the loss of conciousness
Ulceration, massive bleeding or infection of the primary tumour were criteria for
ear ablation as described above. Animals were anaesthetized with 0.02 mg/kg body
weight glycopyrrolate s.c., 5 mg/kg body weight xylazine i.m., 70 mg/kg body weight
ketamine i.m. and up to 10 mg/kg body weight pentobarbital i.v. when necessary.
Laparotomy was done. The aorta abdominalis was punctured and blood was taken
for analysis. Sacrifice was induced by bleeding to death and by inducing a pneu-
mothorax.
3.6.2 Dissection
The dissection was carried out in a standard manner for each rabbit. The size of the
primary tumour was measured in three dimensions.The draining lymph node stations
of both auricles had been identified and removed. In detail, these were the parotid
lymph nodes, the caudal mandibular lymph nodes and the rostral mandibular lymph
nodes (31). All lymph nodes had been weighed, a photo was made and the largest
diameter of each lymph node was measured and documented. The next step was
removal of the thorax organs. Therefore, the skin was detached from the underlying
rips and a sternocostal block was cut out and removed. The trachea was accessible
and could be cut through in its proximal part. The whole thorax organs could
be removed from the thorax by yanking the trachea. This block was weighed in
toto. Then the lung was seperated and both lobes were weighed. Metastases which
were macroscopically visible were counted. To get a range of the size of visible
metastases, the diameters of the largest and the smallest metastases were measured.
The trachea was opened and observed for metastases. Photo documentation of the
lung was done. The thoracic cavity was inspected for the presence of metastases.
Afterwards the abdomen was inspected. Special regard was drawn to the presence of
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metastases and to the presence of adverse effects of the intraperitoneal gas therapy
(for example adhesions, scars, signs of inflammation).
3.7 Consecutive immune suppression study
3.7.1 Overview
Six rabbits of the O3/O2 gas mixture therapy group had no visible tumour or palpa-
bel enlarged lymph nodes at the end of the observation period on day 90. In other
words, they were probably tumour-free and cured. To exclude metastatic spread to
the lungs, a computed tomography of the thorax was performed in these animals.
Thereafter, these six NZW rabbits were randomly divided into two groups. One
group was immune suppressed (group A1; n = 3 rabbits), while the other group
remained untreated (group A2; n = 3 rabbits). Two additional rabbits (not part
of the previous study) were used. One was immune suppressed to monitor possible
effects of the immune suppression on the tumour take-rate. The other one was only
sham-treated and served as control for the aggressiveness of the tumour cell suspen-
sion. The tumour cell suspension was (re-)inoculated into both auricles of all rabbits
to enhance the number of possible tumours. The technique of inoculation was the
same as described above. Immune suppression was started 2 days (day -2) before
the (re-)inoculation (day 0) and was maintained for 11 consecutive days. On day
14 after tumour cell inoculation, the retake-rate was assessed. Up to that day, the
animals were monitored as described in the corresponding part of the main study.
The study protocol is schematically presented in Figure 3.3.
3.7.2 Computed tomography
Rabbits were premedicated with 0.02 mg/kg body weight glycopyrrolate injected
subcutaneously and then anaesthetized with a combination of 5 mg/kg body weight
xylazine and 30 mg/kg body weight ketamine, both injected intramuscularly. The
Siemens Somatom Plus 4 (Siemens, Erlangen, Germany) was used for this purpose.
All images were regarded by an experienced radiologist of the Department of Di-




Figure 3.3 – Consecutive immune suppression study, experimental design.
The six rabbits of the main study with complete tumour remission (O3/O2 gas mixture ther-
apy group) on day 90 were randomly divided into two groups. Group A1 (n = 3) received an
immune suppression, group A2 (n = 3) was sham-treated. Immune suppression was started
on day -2 with dexamethasone and cyclosporin A and was maintained by daily application
of cyclosporin A up to day 10. On day 0 the tumour cell suspension was (re-)inoculated into
both auricles of all animals. Two additional rabbits were used: one was immune suppressed
likewise the rabbits in group A1, the other rabbit was sham-treated. Both rabbits received
a tumour cell inoculation into both auricles on day 0. The tumour take-rate was assessed
on day 14. Abbreviations: Dex, dexamethasone; CSA, cyclosporin A.
3.7.3 Immune suppression
Two days prior to tumour cell (re-)inoculation, the immune suppression was started.
A single subcutaneous injection of 1.5 mg/kg body weight dexamethasone (Dex,
Dexa®, Jenapharm, Jena, Germany) was applied together with a subcutaneous
injection of 20 mg/kg body weight cyclosporin A (CSA, Sandimmun®, Novartis
Pharma, Nuremberg, Germany). Immune suppression was maintained by daily ap-
plications of 20 mg/kg body weight CSA for 11 consecutive days.
3.8 Statistics
For comparison of survival rates of the three experimental groups the log rank test
was performed considering p < 0.05 as significant. The survival probability of rab-
bits calculated from the time of tumour cell inoculation until day 90 was depicted
according to the Kaplan-Meier method. The time to tumour clearance (TTC) prob-
ability was calculated from the time when the size of the solid auricular tumour
dropped under 5% of the size measured on day 14 after tumour cell inoculation, a
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time point when a solid auricular tumour had developed and gas insufflation ther-
apies or sham treatment started. Statistical differences in mean tumour surface
areas A between the three experimental groups were evaluated with the unpaired
Student’s t-test. To evaluate statistical differences of the mean body weight within
each group the paired Student’s t-test was used. Comparison of the blood param-
eters prior to the first gas insufflation or sham treatment (day 14) with those 24
hrs after the last gas insufflation or sham treatment (day 19) within each group was
done with the paired Student’s t-test. The difference of the mean weight of lymph
nodes of the right and left neck side in all cured animals of the O3/O2 gas mixture
therapy group was calculated with the unpaired Student’s t-test. For all calculations
with the Student’s t-test p < 0.05 was considered as significant.
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From the total of 48 animals that received a tumour cell inoculation into the right
auricle 7 were excluded from the study due to different reasons. Tumour induction
failed in only one animal (2.1%). Other reasons for exclusion from the study were
death due to anaesthesia complications, death in a transport box and death prior
to treatment due to undefined reasons.
4.1 Clinical measurements
4.1.1 Survival
The observation period of the experiment ended on day 90 after inoculation of the
tumour cell suspension. This time point was chosen since the highly malignant
VX2 tumour model is characterized by a mortality rate of 100% within 90 days,
independent of the localization of the tumour.
For survival analysis rabbits were assigned to two different groups: survival and
non-survival. Survival corresponds to two situations. First situation: The animal
survived until day 90, the auricle was not resected and macroscopically tumour-free,
no enlarged lymph node could be palpated. These animals were defined as cured
(O3/O2 cured, O2 cured, sham cured). Second situation: The animal survived
until day 90, the auricle was not resected but not tumour-free and/or enlarged
lymph nodes could be palpated. These animals survived, but they were not cured
(O3/O2 survived, O2 survived, sham survived). Non-survival also corresponds to
two situations. First situation: The tumour-bearing auricle was resected within 90
days after tumour induction, the rabbit thereafter survived until day 90. These
animals could no longer be assigned to the survival group, because an earlier death
due to infection or bleeding of the auricle would have been very likely without an
ear ablation (O3/O2 ablation, O2 ablation, sham ablation). Second situation: The
animal was sacrificed before day 90 due to the defined end point criteria or died
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spontaneously (O3/O2 dead, O2 dead, sham dead).
O3/O2 group
Of the 14 rabbits that received intraperitoneal insufflations of the O3/O2 gas mix-
ture, seven (50.0%) survived. On day 90, six (42.9%) could be defined as cured.
The auricle of the seventh animal that survived, still beared a large mass of tissue
with a brownish firm cap on day 90. Seven animals (50.0%) fulfilled the criteria for
non-survival. Four of these seven survived until day 90, but had an ear ablation be-
fore. The ear resections were carried out on days 50, 81, 85 and 85. One animal died
spontaneously on day 72 (ear ablation day 48), the remaining two were sacrificed
according to the defined endpoint criteria on day 41 (no previous ear resection) and
day 58 (ear resection day 48).
O2 group
Of the 13 rabbits that received intraperitoneal insufflations of the O2 gas, three
(23.1%) survived. On day 90, two (15.4%) could be defined as cured. The auricle
of the third animal that survived, still beared a large tumour mass. Ten animals
(76.9%) fulfilled the criteria for non-survival. Four of these ten survived until day
90, but had an ear ablation before (days 31, 50, 51, 57). Three animals died sponta-
neously (days 26 (no previous ear ablation), 46 (ear ablation day 45), 70 (no previous
ear ablation)) and three were sacrificed according to the defined endpoint criteria
(days 39 (ear ablation day 32), 73 (ear ablation day 56), 80 (ear ablation day 51)).
Sham group
Of the 14 rabbits that received sham treatment, one (7.1%) survived. This rabbit
was defined as cured. 13 animals (92.9%) fulfilled the criteria for non-survival. Two
of these 13 survived until day 90, but had an ear ablation before (days 47, 54). Of
the remaining 11 animals one died spontaneously on day 55 (ear ablation day 30),
while ten were sacrificed according to the defined endpoint criteria (days 35 [no], 55
[47], 55 [32], 55 [41] , 68 [51], 71 [48], 75 [no], 75 [41], 81 [57], 86 [48]); in [ ] is given




A Kaplan-Meier plot showing the 3-month survival probability is depicted in Figure
4.1. Calculated with the log rank test, the survival probability of the rabbits in
Figure 4.1 – Survival analysis. Kaplan-Meier survival curves for VX2 tumour-
bearing NZW rabbits that received O3/O2 therapy (n = 14), O2 therapy (n =
13) or sham treatment (n = 14) from day 14 to day 18 after tumour induction.
In the O3/O2 therapy group 7/14 animals survived (50.0%), in the O2 therapy group 3/13
animals survived (23.1%) and in the sham treatment group 1/14 (7.1%) survived until the
end of the observation period 90 days after tumour cell inoculation into the right auricle.
Statistical analysis was done with the log rank test. O3/O2 gas mixture therapy significantly
increased the survival probability compared with the sham treatment (p = 0.0006***), but
did not increase the survival probability compared with the O2 gas therapy (p = 0.0559).
The difference of the survival probability between the O2 gas therapy group and the sham
group was not statistically significant (p = 0.2448). For calculation all animals with an
ear resection were defined as “dead” from the time when the ear resection was carried out.
Abbreviation: ns, not significant.
the O3/O2 gas mixture therapy group (50.0% survival) was significantly increased
compared with the survival probability of the rabbits in the sham treatment group
(7.1% survival) (p = 0.0006). The survival probability of the rabbits in the O3/O2
gas mixture therapy group was not significantly different from the survival proba-
bility of the rabbits in the O2 gas therapy group (23.1% survival) (p = 0.0559), but
this p value suggests a tendency towards an increased survival in the O3/O2 gas
mixture therapy group. The difference of the survival probability between the O2
gas therapy group and the sham group was calculated nonsignificant (p = 0.2448).
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4.1.2 Growth of the primary tumour
Mean tumour surface area A
The tumour surface area A is the product of the largest diameter of the tumour and
the diameter perpendicular to that. The development of the mean tumour surface
areas A of the three experimental groups is shown in Figure 4.2. The mean tumour
Figure 4.2 – Growth of the primary tumour. Development of the mean tumour
surface areas A of the three experimental groups from day 5 (day 0 - inoculation
of VX2 cell suspension) to day 30.
The tumour surface area A is the product of the largest diameter of the tumour and the
diameter perpendicular to that and is denoted in mm2. The means of the three groups were
compared for each day with the unpaired Student’s t-test. Compared with the sham group,
the mean tumour surface area of the O3/O2 group was significantly smaller from day 27 to
day 30. Compared with the sham group, the mean tumour surface area of the O2 group
was significantly smaller on days 10 and 11 and from day 14 to day 30. Compared with
the O3/O2 group, the mean tumour surface area of the O2 group was significantly smaller
from day 16 to day 20. The corresponding p-values are given in the main text. Note that
on day 14 (just prior to the first insufflation of the O3/O2 gas mixture into the peritoneum)
no statistically significant difference was observed comparing the mean tumour surface area
of the O3/O2 group with the two control groups. For better optical clarity, the error bars




surface area A on day 14 (directly before the first treatment was started) was 415.4
± 94.9 mm2 for the O3/O2 group, 364.7 ± 91.9 mm2 for the O2 group and 504.2
± 200.4 mm2 for the sham group. The difference of the mean tumour suface areas
between the O3/O2 group and the sham group was not statistically significant (p =
0.146, unpaired Student’s t-test). The difference of the mean tumour surface areas
of the O3/O2 group and the O2 group was also not statistically significant (p =
0.171). The tumour surface areas of the animals in the O2 group were significantly
smaller than those of the animals in the sham group (p = 0.031).
Beginning on day 14 after inoculation of the tumour cell suspension into the
right auricle, the gas insufflations (O3/O2 gas mixture or pure O2 gas) or the sham
treatments were performed on five consecutive days. On day 19, the first day after
the last gas insufflation or sham treatment, the mean tumour surface area A of the
O3/O2 group was 562.0 ±166.1 mm2. The mean tumour surface area A of the O2
group was 423.4 ±128.1 mm2 and of the sham group was 683.2 ±270.0 mm2. The
difference of the mean tumour surface areas between the O3/O2 group and the sham
group was not statistically significant (p = 0.165, unpaired Student’s t-test). The
mean tumour surface area of the animals in the O2 group was significantly smaller
than the mean tumour surface area of the animals in the O3/O2 group (p = 0.023)
and than that of the animals in the sham group (p = 0.004).
As shown in Figure 4.2, the mean tumour surface area A of the O3/O2 group
reached a maximum on day 22 and then decreased in size. Compared with the
mean tumour surface area of the sham group, the mean tumour surface area of the
O3/O2 group was significantly smaller from day 27 (p = 0.031) to day 30 (p =
0.006). As mentioned above, the mean tumour surface area of the O2 group was
significantly smaller than that of the sham group from day 14 to day 30. Comparing
the mean tumour surface area of the O2 group with that of the O3/O2 group, the
mean tumour surface area of the O2 group was significantly smaller only from day
16 to day 20 after inoculation of the tumour cell suspension. More importantly,
after day 20 the difference was not statistically significant. Data analysis is shown
up to day 30 after tumour induction. After day 30, the first tumours had regressed




As described previously by van Es et al. (88), hyperaemia of the auricle and a purple
discoloration of the skin adjacent to the tumour normally come along with progres-
sive growth of the tumour. The disappearance of these vascular signs was an im-
portant first clinical sign of beginning tumour regression after local IL-2 treatment.
Their observation could be confirmed in this study. The hyperaemia disappeared
and the skin adjacent to the tumour became more brightly, similar to the normal
colour of the rabbits’ auricular skin. Different stages of tumour regression in macro-
scopic view are shown exemplary in Figure 4.3. Pictures A-D demonstrate regression
of the primary auricular tumour after O3/O2 gas mixture treatment until complete
remission. In contrast, pictures E-H demonstrate progression of the tumour to the
final stage in an animal of the sham group. Picture A shows the tumour 14 days
after inoculation of the tumour cell suspension. At that time point, the tumour was
growing fast and the tumour tissue had a viable aspect. A thin crust had developed
at the top, probably a dried exsudate. The situation 13 days later (day 27 after
tumour cell inoculation) in the same animal is shown in picture B. The surface area
A had decreased in size. The former viable tumour tissue was now replaced by a dry,
firm, brown to black necrotic mass. This macroscopical change from a viably looking
tumour mass to a totally necrotic looking mass in some rabbits began one or two
days after the first day of treatment. Typically, the described necrotic appearence
was observed for some days without mentionable change. Finally, the necrotic mass
dropped off, resulting in a situation shown in Picture C (day 35 after inoculation
of the tumour cell suspension). A small, nearly round defect in the skin with a
surrounding pink circle appeared at the site where the necrotic mass had dropped
of. Macroscopically, no viable tumour tissue was visible. The end stage was a small
scar at the site of the former auricular tumour. This scar is depicted in Picture D
(day 90 after inoculation of the tumour cell suspension).
The exact days after tumour cell inoculation on which the primary tumours had
disappeared completely are summarized in Table 4.1. Figure 4.4 depicts a Kaplan-
Meier plot showing the time to tumour clearance (TTC) probability in the three
experimental groups. The TTC probability was calculated from the time when the
size of the solid auricular tumour dropped under 5% of the size measured on day
14 after tumour cell inoculation. The TTC probability, calculated with the log
rank test, in the O3/O2 gas mixture therapy group (42.9% complete remission) was
30
Results
Figure 4.3 – Growth and development of the VX2 tumours after inoculation of
the tumour cell suspension in the right ear of NZW rabbits.
Pictures A-D show representative macroscopic views of a solid VX2 tumour in the right ear
of a rabbit on day 14 after tumour cell inoculation (A) and different stages of remission after
O3/O2 gas mixture therapy (B-D). Note that only a small scar of the remitted auricular
tumour remained on day 90 (D), the end point of our observation period. In sharp contrast,
in rabbits that succumbed to tumour progression the auricular tumour continued growing,
resulting in severe ulcerations associated with massive bleeding and onset of local infections,
introducing the final stage of this tumour disease (representative stages of the same rabbit
are shown in pictures E-H). Depicted are tumour stages on day 14, 27, 35, and at the end
of the observation period (90 days (D) or 42 days in case of death (H)).
significantly higher than that of the sham group (7.1% complete remission) (p =
0.0243). The difference between the TTC probability of the O3/O2 group and the O2
group (15.4% complete remission) was not significant (p = 0.0665). The regression
process of the two tumours in the O2 group lasted considerably longer than that of




Table 4.1 – Complete remission of the primary auricular tumour
rabbit no. treatment group complete remission of










Abbreviations: no., number; p.i., post inoculation
Figure 4.4 – Complete tumour remission. Kaplan-Meier plot showing the time
to tumour clearance (TTC) probability in rabbits that have developed a solid
auricular VX2 tumour on day 14 after VX2 tumour cell inoculation.
The TTC probability significantly varied between O3/O2-treated and sham-treated rabbits
(p = 0.0243*) but not between O3/O2- and O2-treated rabbits (p = 0.0665). Furthermore,
there was no significant difference in the TTC probability between the O2 group and the
sham group (p = 0.5781). Abbreviation: ns, not significant.
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4.1.3 Lymph node palpation
Cured rabbits
Palpation of the necks of cured animals showed that all animals had an enlarged first
echolon parotid lymph node on the right neck side at the beginning of the treatment
period on day 14 after inoculation of the tumour cell suspension.
Table 4.2 summarizes the results found by lymph node palpation of all cured an-
imals. At the beginning of the experiment all parotid lymph nodes of the cured
Table 4.2 – Initial growth and subsequent regression of parotid lymph nodes of
the cured rabbits
rabbit treatment enlarged lymph disappearance
no. group node day 14 p.i. day p.i.
1 O3/O2 yes 43
6 O3/O2 yes 47
14 O3/O2 yes 49
15 O3/O2 yes 64
19 O3/O2 yes -
33 O3/O2 yes 56
16 O2 yes -
48 O2 yes 89
23 Sham yes 84
Abbreviations: no., number; p.i., post inoculation
animals enlarged progressively until they reached a maximum size. The parotid
lymph nodes of the two animals of the O2 group grew larger (largest diameter up
to 2.0 cm) than all other parotid lymph nodes of the cured animals. This finding is
consistent with the finding that the primary tumours disappeared later than those
of the animals of the O3/O2 group with complete tumour remission. Once hav-
ing reached the maximum size, growth of the parotid lymph nodes stagnated. The
same lymph node sizes could be observed for several days or few weeks. Then all
parotid lymph nodes decreased in size. Finally, most of the lymph nodes could not
be palpated any more. The days at which the parotid lymph nodes had disappeared
completely are given in the right column of the table. In two animals with complete
remission of the primary auricular tumour the parotid lymph node did not disap-
peare completely. These two lymph nodes had a maximum size of 1.5 cm and 2.0
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cm. At the end of the observation period only very small nodules could be palpated.
Thus, the decrease in size of these two lymph nodes was remarkably as well.
All other rabbits
The parotid lymph nodes of all other animals were enlarged at the beginning of
the treatment period. The lymph nodes were growing progressively after the end
of the treatment period until the end of the observation period or until the animal
was sacrificed. The weights of the lymph nodes at autopsy are given in Section 4.2,
“Findings at autopsy”.
4.1.4 Body weight
The development of the body weight in the early phase of the experiment is depicted
in Figure 4.5. Until day 14 after tumour cell inoculation the mean body weight of
the rabbits in all treatment groups increased. This indicates that the developing
tumour in the early phase had no substantial influence on the rabbits’ general health
condition.
The daily treatment procedure, beginning on day 14 and ending on day 18, caused
a statistically significant body weight loss of rabbits in the O3/O2 group and in the
O2 group, but not in the sham group (calculated with the paired Student’s t-test).
Compared with the mean body weight before the first treatment on day 14, the
weight loss was statistically significant from day 15-23 (p < 0.01) and from day 24-
26 (p < 0.05)in the O3/O2 group. In the O2 group the weight loss was statistically
significant on day 15 and day 19 (p < 0.05) and from day 16-18 (p < 0.01). In the
sham group, the weight loss was not statistically significant at all. The mean body
weight, expressed in % of the mean body weight on day 14, reached its minimum in
the O3/O2 group and in the O2 group on day 18 after tumour induction, the last day
of the daily therapeutic treatment. The maximum drop of the mean body weight
was 8.3% in the O3/O2 group, 5.1% in the O2 group and 2.2% in the sham group
(on day 16 post tumour cell inoculation) compared with the mean body weight on
day 14. Note that the mean body weight twelve days after the last treatment (day
30) was comparable in all three groups (2.99 kg O3/O2 group, 2.96 kg O2 group,
3.01 kg sham group).
The mean body weight of all animals of the survival group constantly increased
from the end of the observation period until day 90, shown in Figure 4.6. In sharp
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Figure 4.5 – Body weight. Development of the mean body weight from day 0
(at which VX2 cell suspension was inoculated) until day 30.
The mean body weights of the three experimental groups are drawn separately. The upper
chart shows the absolute body weight in kg. For the lower chart, the mean body weight
on day 14 was set 100% and changes were calculated relative to the body weight on day
14. Changes of the mean body weight within each group compared with the mean body
weight on day 14 (the day when the treatment was started) were calculated with the paired
Student’s t-test. In the O3/O2 group, the body weight loss was significant from day 15 to
day 26 (p < 0.01 day 15-23 and p < 0.05 day 24-26). In the O2 group, the body weight loss
was significant from day 15 to day 19 (p < 0.05 day 15 and day 19 and p < 0.01 day 16-18).
The weight loss in the sham group was statistically not significant. On day 30, twelve days
after the therapy was finished, the mean body weight of the rabbits in the different groups
did not differe. For improved optical clarity, the error bars (standard deviation) are plotted
only in one direction. The treatment period is marked with a grey box.
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Figure 4.6 – Body weight. Development of the mean body weight of all animals
that survived until day 90.
The mean body weight in all three treatment groups was constantly increasing from day
19 (the first day after the end of the treatment period) to day 90 after tumour induction,
indicating that the animals were in good health condidtion. For improved optical clarity,
the error bars (standard deviation) are plotted only in one direction. The treatment period
is marked with a grey box. The development of the body weight of one sham-treated animal
that was sacrificed on day 68 due to a body weight loss >15% is shown for comparison in
this graph. At autopsy, numerous metastases in the lung were detected in that rabbit.
contrast, tumour-induced cachexia occured in the late phase of the experiment in
several animals of the non-survival group with progressive tumour growth. A rapid
or consistent weight loss above 15-20% of the maximal body weight was a defined
end point of the study. Van Es et al. found, that animals with a weight-loss of
about 11.7% to 22.3% regularly had advanced pulmonary metastases (89). The
development of the body weight of one sham-treated animal with severe disease is
depicted in Figure 4.6.
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4.1.5 Haematological and clinical chemistry blood parameters
To test for adverse effects of the O3/O2 therapy, arterial blood samples were taken
on day 14 (before the beginning of the treatment period) and on day 19 (one day
after the last treatment). To test for late adverse effects of the repetitive O3/O2-
pneumoperitoneum, additional blood samples of the six animals with complete tu-
mour remission were taken on day 90 after tumour cell inoculation (the end of the
observation period). Statistic differences between day 14 and day 19 in each ex-
perimental group were calculated with the paired Student’s t-test and statistically
significant changes were marked with p < 0.05∗, p < 0.01∗∗, p < 0.001∗∗∗ in Fig-
ure 4.7 and Table 4.3, which summarizes the results. Measurement of the blood
Table 4.3 – Effect of repetitive O3/O2-PP, O2-PP and sham treatment on stan-
dard laboratory blood parameters.
O3/O2 (n=14) O2 (n=13) Sham (n=14) O3/O2 reference
d14 d19 d14 d19 d14 d19 d90 values (85)
WBC 8.6 11.4∗∗∗ 8.5 10.6∗ 8.6 10.7 7.6 2.5-9.8 (103/mm3)
GRA 3.4 5.5∗∗∗ 3.1 4.8∗ 3.5 4.9∗ 1.8 1.6-3.7 (103/mm3)
LYM 4.9 5.7 5.3 5.4 4.9 5.6∗ 5.6 3.3-7.0 (103/mm3)
MO 0.2 0.3∗ 0.2 0.3 0.2 0.3 0.1 0.0-0.4 (103/mm3)
RBC 5.85 5.55 5.68 5.31 5.64 5.59 5.91 5.20-6.80 (106/mm3)
HGB 11.7 11.6 12.5 11.1 10.0 11.5 12.9 9.8-14.0 (g/dl)
HCT 38.4 36.4 39.0 38.9 35.8 36.1 40.2 36.0-47.0 (%)
CREA 0.736 0.863∗∗ 0.743 0.935 0.787 0.800 0.848 0.5-2.6 (mg/dl)
GOT 17.39 13.73 14.20 8.94 15.15 13.72 29.72 8.0-56.0 (U/l)
GPT 34.7 27.3 34.7 21.6 22.9 21.0 74.9 18.0-123.0 (U/l)
Significant changes are marked with yellow colour.
parameters on day 19 (24 hrs after the last gas insufflation or sham treatment) re-
vealed a statistically significant increase of the WBC count in the O3/O2 group (p
< 0.001∗∗∗) and in the O2 group (p < 0.05∗) compared with the WBC count on day
14. The increase of the WBC count in sham treated rabbits was statistically not
significant. The increase of the WBC count was rather caused by an increase of the
GRA count than by an increase of the LYM or MO count. The increase of the GRA
count was statistically significant in all three treatment groups (p < 0.001∗∗∗ in the
O3/O2 group and p < 0.05
∗ in the O2 group and the sham group). The O3/O2-PP
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Figure 4.7 – Effect of repetitive O3/O2-PP on standard laboratory blood param-
eters. Shown are selectively the blood parameters of the O3/O2 group. Statistic differences
between day 14 and day 19 were calculated with the paired Student’s t-test and significant
differences are marked with asterisks (p < 0.05*, p < 0.01**, p < 0.001***). Abbreviations:
WBC, white blood cells; GRA, granulocytes; LYM, lymphocytes; MO, monocytes; RBC,
red blood cells; HGB, haemoglobin; HCT, haematocrit; CREA, creatinine; GOT, glutamic
oxaloacetic transaminase; GPT, glutamic pyruvic transaminase.
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and the O2-PP had no significant influence on the RBC count, HGB values and
on HCT values. The values of the liver function parameters (GOT and GPT) and
CREA values remained within the physiological range. Nevertheless, there was a
statistically significant increase in the CREA values of the O3/O2 treated rabbits (p
< 0.01∗∗) on day 19 compared with the values on day 14.
On day 90 after tumour cell inoculation, all measured arterial blood parameters
of the six O3/O2 treated animals with complete tumour remission were within the
physiological range. The slightly increased values of the WBC count and the GRA
count observed on day 19, had fallen to lower values in the interim time.
4.1.6 Blood gas analysis
In some animals, arterial blood gas analysis was performed in addition to haema-
tological and clinical chemistry investigations. Arterial blood gas analysis was done
on day 14 (before the beginning of the treatment period) and on day 19 (24 hr after
the last treatment). The results are summarized in Table 4.4 and Figure 4.8.
Table 4.4 – Effect of repetitive O3/O2-PP, O2-PP and sham treatment on arterial
pH, pO2 and pCO2 values
O3/O2 (n=9) O2 (n=11) Sham (n=11)
d14 d19 d14 d19 d14 d19
pH 7.462 7.478 7.460 7.500 7.451 7.464
pO2 79.0 72.3 77.8 75.7 80.6 77.3
pCO2 37.6 35.2 35.5 33.3 36.9 37.1
Repetitive O3/O2-PP, O2-PP or sham treatment caused no statistically significant
changes of arterial pH, pO2 and pCO2 values (calculated with the paired Student’s
t-test in each experimental group).
4.1.7 Microbiological analysis of infected primary tumours
To prevent rabbits from early death due to severe local infection at the primary
tumour site or massive bleeding in the course of the primary tumour development
ablation of the ear was performed under anaesthesia. The time points at which the
ear resections were carried out have already been given in the subsection “survival
analysis”. Clinically, signs of a local infection (redness, swelling, foul odour, heat to
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Figure 4.8 – Effect of repetitive O3/O2-PP on arterial blood gas parameters.
Shown are selectively the blood gas parameters of the O3/O2 therapy group. Statisitic
differences between day 14 and day 19 were calculated with the paired Student’s t-test. No
significant differences were observed.
the site) of the tumour-bearing auricle were found in all animals before the resection
was performed. The following microorganisms were found in smears of the infected
necrotic tumour tissue: Enterobacter cloacae, Enterococcus faecalis, Escherichia coli,
Kluyvera ascorbata, Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus
aureus. Except for Kluyvera ascorbata, all these bacteria are found in the normal
intestinal flora of healthy rabbits and dogs (17). Kluyvera ascorbata is seen as
an infrequent, probably opportunistic pathogen in humans, which was isolated in
human sputum, urine and stool (34). Pasteurella multocida, the most common
bacterial pathogen of rabbits, wasn’t isolated at all (85).
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4.2 Findings at autopsy
4.2.1 Lymph nodes
Lymphogenic metastatic spread of the VX2 auricle carcinoma frequently occurs to
the parotid lymph node and, in the course of the disease, to the caudal mandibular
lymph nodes (31). Normally, no metastatic spread to the third draining lymph
node station of the auricle (rostral mandibular lymph nodes) is found (31). For all
animals that were sacrificed or died spontaneously, an autopsy was carried out in a
standard manner, as described in the chapter “Material and methods”.
All animals of the O3/O2 gas therapy group with complete tumour remission at
the end of the observation period were included in a consecutive immune suppression
study. At the end of this study, they were sacrificed as well and an autopsy was
carried out. As described later, in all three animals that received the tumour cell
re-inoculation without concomitant immune suppression tumour induction failed.
Therefore, development of lymph node metastases due to re-inoculation of the tu-
mour cell suspension seems very unlikely. Comparison of the weight of the lymph
nodes of the right (ipsilateral to the auricular tumour) and left (contralateral to
the auricular tumour) neck side in these animals can thus give information on lym-
phogenic metastatic spread of the initial right auricular tumour. In those cured
animals with tumour re-induction without concomitant immune suppression (n =
3), the mean weight of the parotid lymph nodes of the right neck side was 0.109 ±
0.042 g . The difference to the mean weight of the parotid lymph nodes of the left
neck side (0.180 ± 0.069 g) was not statistically significant (p = 0.203, unpaired
Student’s t-test). The mean weight of the caudal mandibular lymph nodes of the
right neck side, 0.046 ± 0.018 g, was also not significantly different from that of the
left neck side, 0.083 ± 0.015 g (p = 0.053). Thus, comparison of the mean weight of
the draining lymph nodes of the initially tumour-bearing right side with the mean
weight of the draining lymph nodes of the contralateral side, revealed no difference
in animals of the O3/O2 gas therapy group with complete tumour remission.
All rabbits that were not cured, had an enlarged right parotid lymph node (ipsi-
lateral to the tumour) compared with the left parotid lymph node (contralateral to
the tumour) at autopsy. The exact weights of the parotid lymph nodes of both neck
sides are given in Table 4.5. The weight of the enlarged right parotid lymph nodes
ranged from 0.9 g in a surviving O2-treated animal to 195.1 g in a sham-treated
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animal that was sacrificed on day 86 after tumour induction. For comparison, the
mean weight of all contralateral parotid lymph nodes listed in the table (n = 30)
was 0.113 ± 0.071 g. Figure 4.9 shows representative macroscopic views of lymph
nodes of the right neck side from an animal of the sham group which succumbed to
the VX2 tumour.
Figure 4.9 – VX2 tumour derived lymph node metastases.
Typical macroscopic views of enlarged and metastatic lymph nodes of the right neck side in
an animal of the sham group. The parotid lymph nodes (A) often were remarkably enlarged,
the caudal mandibular lymph nodes (B) sometimes were enlarged, the rostral mandibular
lymph nodes (C) are normally not affected. Note, that the parotid lymph nodes and the
caudal mandibular lymph nodes are normally only slightly larger than the rostral madibular
lymph nodes.
4.2.2 Lungs
Haematogeneous metastatic spread to the lungs represents a characteristic feature
of the VX2 auricle cancer (32). Therefore, the thoracic cavity was examined for
the presence of macroscopic metastases. Complete thorax scans using CT were
performed for all rabbits with complete remission of the primary tumour at the end
of the observation period (day 90 after tumour cell inoculation). Typical results of
the macroscopic examination and of CT scans are shown in Figure 4.10.
Animals with complete tumour remission in all three treatment groups were free
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Table 4.5 – Weight of parotid lymph nodes and lung metastases at autopsy
no. autopsy (d) Parotid LN Parotid LN Metastases
ipsilateral (g) contralateral (g) lungs
O3/O2 survived
10 90 92.5 – no
O3/O2 ablation
8 90 130.7 0.108 no
13 90 18.8 0.038 no
18 90 41.6 0.048 no
28 90 50.4 0.065 no
O3/O2 dead
26 58 102.4 0.022 yes
30 41 2.9 0.201 no
31 72 68.3 0.100 yes
O2 survived
42 90 0.9 0.118 no
O2 ablation
35 90 190.4 0.177 yes
43 90 23.4 0.264 no
45 90 78.3 0.188 no
46 90 86.2 0.224 yes
O2 dead
21 39 8.1 0.065 yes
25 70 21.9 0.034 no
37 26 1.7 0.049 no
39 73 46.4 0.071 yes
40 46 43.1 0.253 no
44 80 43.5 0.209 no
Sham ablation
17 90 67.3 0.067 yes
34 90 137.0 0.081 no
Sham dead
2 55 27.9 0.143 yes
4 68 178.7 0.133 yes
9 86 195.1 – yes
12 71 94.9 0.031 yes
20 55 46.1 0.174 no
22 55 87.2 0.066 yes
24 75 53.9 0.144 no
27 75 3.7 0.083 yes
29 55 60.1 0.061 yes
32 81 134.3 0.136 yes
36 35 2.4 0.028 no
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Figure 4.10 – VX2 tumour derived distant lung metastases.
CT scans of the thorax showing no detectable lung metastases in a rabbit of the O3/O2
group with complete tumour remission (a) at the end of the observation period, but reveals
a huge metastasis in the lung of a rabbit on day 32 (b, asterisk) that succumbed to the VX2
tumour later on (depicted are representative CT scans of the lungs amounting to the vena
pulmonalis). The lower images show macroscopic views of the complete lungs of a healthy
rabbit (c) and of an animal with multiple VX2 carcinoma derived lung metastases at the
pleura visceralis (d).
of lung metastases on CT scans. Of the other animals, in 2/8 (25.0%) of the O3/O2
group, 4/11 (36.4%) of the O2 group and 9/13 (69.2%) of the sham group pulmonary
metastases were present on macroscopic examination (Table 4.5; no macroscopic
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lung metastases - cell marked with green colour, macropscopic lung metastases -
cell marked with red colour).
O3/O2 group
The one animal that survived but still beared a large tumour mass (O3/O2 survived),
was free of lung metastases. Those four animals which received an ear resection and
then survived until day 90 (O3/O2 ablation) were free of lung metastases as well.
The animal that died spontaneously (O3/O2 dead) had multiple lung metastases
at autopsy. Of the two animals that were sacrificed (O3/O2 dead) before day 90
after tumour cell inoculation, one had macroscopic lung metastases while the other
showed a large lung abscess (Staphylococcus aureus was isolated) but no metastases.
O2 group
The one animal that survived but still beared a tumour mass (O2 survived) was free
of lung metastases. Of those four animals that survived but had an ear ablation
before(O2 ablation), 2 had macroscopic lung metastases at autopsy. None of the
three animals that died spontaneously (O2 dead) had macroscopically visible lung
metastases. In two of them infection of the lungs was found (in one animal Klebsiella
pneumoniae and in the other Staphylococcus aureus was isolated). Of the three
animals that were sacrificed before day 90 post tumour induction (O2 dead), two
had macroscopic lung metastases.
Sham group
Of those two animals that survived but had an ear ablation before (Sham ablation),
one had macroscopic lung metastases, the other one was free of lung metastases.
The one animal that died spontaneously (Sham dead) had no lung metastases. Of
the ten animals that were sacrificed before day 90 post tumour induction (Sham
dead), 8 had macroscopic lung metastases. One of the two other animals had a lung
abscess due to infection with Staphylococcus aureus.
Comparison of some aspects of lung metastases
The number of unique tumour nodules per animal (both lungs) was 4 and 10 in
the O3/O2 group, varied from 2 to 50 in the O2 group and from 1 to 70 in the
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sham group. To quantify the tumour mass, the weight of the lung of each animal
was measured. The mean weight of all metastatic lungs was 20.15 ± 6.15 g in the
O3/O2 group (n = 2), 54.43 ± 37.05 g in the O2 group (n = 4) and 32.96 ± 31.62
g in the sham group (n = 9). For comparison, the mean weight of all lungs with no
metastases was 12.34 ± 3.47 g.
4.2.3 Abdominal cavity
As described above, the O3/O2 gas mixture or the O2 gas were insufflated in the
abdominal cavity. Therefore, special regard was pointed to the inspection of the
abdominal cavity to search for adverse effects of the pneumoperitoneum. In all
cases, the abdominal organs were easy moveable and no adhesions, scars or signs of
inflammation could be detected.
4.3 Consecutive immune suppression study
Van Es et al. made the observation that reimplanted VX2 tumour cells were rejected
in rabbits with tumour remission after perilesional treatment with IL-2 (88). To
test whether reimplanted VX2 tumour cells are also rejected in rabbits with tumour
remission after O3/O2-PP, we performed a consecutive study with the six cured
animals of the O3/O2 group. The six animals were randomly divided into two groups.
Rabbits in the first group (n = 3) were immune-suppressed with Dex and CSA as
described above. Rabbits in the second group were sham-treated (n = 3), receiving
no immunosuppressants. All animals received a bi-auricular injection of the VX2
tumour cell suspension. The development of the tumours was observed for 90 days.
The results are summarized in Table 4.6. As expected, all sham-treated animals
were protected for tumour retake. In sharp contrast, immune suppressed animals
developed tumours in 4 out of 6 tumour cell reinoculations. Tumour growth and
size in these animals did not show any difference to the auricular tumours previously
measured in immune competent rabbits of the sham group.
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Table 4.6 – Retake-rate of auricular VX2 tumours
group animals (n) tumours (n)
O2/O3-rem + Dex/CSA 3 4/6
O2/O3-rem + sham 3 0/6
Control + Dex/CSA 1 1/2
Control + sham 1 2/2
Abbreviations: rem, remission; Dex, dexamethasone; CSA, cyclosporin A
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5 Discussion
5.1 General study results: survival, growth and
regression of the primary tumour, metastatic
spread
The aim of the study was to test if intraperitoneal application of a medical O3/O2 gas
mixture (O3/O2-PP) could represent an effective antitumour approach as proposed
after preliminary observations in NZW rabbits bearing the VX2 carcinoma (4). Sur-
vival analysis showed that the repetitive intraperitoneal application of the O3/O2
gas mixture significantly increased the 3-month survival rate of VX2 tumour-bearing
NZW rabbits compared with the 3-month survival probability of sham-treated rab-
bits. Furthermore, it could be denoted that complete remission of the VX2 auricle
carcinoma after repetitive O3/O2-PP occured at a significantly higher rate than
spontaneous complete remission in sham-treated animals.
It is of importance to distinguish true remissions from so-called “non-takes”. In
some cases this can cause difficulties, since a reactive swelling at the inoculation site
always occurs in the first week after tumour cell transplantation (89). Van Es et al.
investigated this problem for the VX2 auricle carcinoma and reported the occurence
of spontaneous tumour regressions in 22% (16/72) of the transplantations, but they
regarded all of them as “non-takes” (89). These tumours/reactive swellings reached
a mean maximum size of 0.8 cm2 ten days after tumour cell inoculation. Progressive
tumour growth was observed for the remaining 78% (56/72) of transplantations
and the occurence of spontaneous true remissions at a later point in time was not
reported. These data suggest that the occurence of spontaneous true remissions of
the VX2 auricle carcinoma is a rare event. In our study the maximum size of the six
tumours in the O3/O2 group that went into remission ranged from 3.0 cm
2 to 8.6
cm2, the mean time after tumour induction at which they reached the maximum size
was 21 days (range 16 - 26 days). Thus, the size of these tumours by far exceeded
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the size that was found for the reactive swellings in “non-takes” and all tumour
remissions in O3/O2-treated animals can be regarded as true remissions. The same
is true for the tumour of the sham-treated animal that reached a maximum size of
4.1 cm2 at day 23 after tumour cell inoculation.
The literature does not contain much information about the frequency of spon-
taneous true remissions of the VX2 auricle carcinoma of untreated NZW rabbits.
A spontaneous remission rate of 41% (9/22) was found, if tumour pieces instead of
tumour cell suspensions were used for tumour induction (89). These tumours had a
mean maximum surface area of 2.4 cm2 21 days after the tumour induction. Despite
the fact that the point in time at which these tumours went into regression was
similar to that found in our experiment, comparison of remission rates makes little
sense, since the tumours in our study were remarkably larger before they went into
regression. Thus, as described previously, it can be expected that spontaneous true
remissions occur infrequent and that the high remission rate of the primary auricular
tumour must be explained by a specific therapeutic effect of the intraperitoneally
insufflated medical O3/O2 gas mixture.
The VX2 auricle carcinoma is characterized by initial lymphogenic metastatic
spread, similar to human HNSCC (32). At the end of the observation period on day
90 after tumour cell inoculation the parotid lymph node (sentinal lymph node) was
not palpable in five of the six animals of the O3/O2 group with complete regression
of the primary tumour. The sixth animal still had a very small nodule, which could
be palpated at the anatomic site of the right parotid lymph node. These results
raise the question, whether the O3/O2 therapy prevented metastatic spread of the
VX2 auricle carcinoma or, whether already existing metastases at the time of the
treatment were cleared by the O3/O2 therapy. Clinically, palpation at day 14 after
tumour induction prior to the first gas insufflation revealed an enlarged ipsilateral
parotid lymph node in all rabbits. This enlargement might be due to metastatic
spread to the lymph node or to reactive processes. Dünne et al. found a single solid
metastasis in 62.5% of histologically investigated ipsilateral parotid lymph nodes
on day 14 after tumour cell inoculation into the subcutis of the auricle (31). In
an other experiment conducted by the same authors, 100% of the rabbits had an
ipsilateral parotid lymph node metastasis on day 18 after inoculation of the tumour
cell suspension (32). Metastatic spread to the ipsilateral caudal mandibular lymph
nodes, which represent the secondary lymph node station, was found 28 days after
tumour induction (31; 32). Thus, the existence of ipsilateral parotid lymph node
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metastases in at least some of the animals during the therapeutical O3/O2 sessions
from day 14 to day 18 is highly likely. Haematogeneous metastatic spread to the
lungs generally occurs later in this tumour model (32). All six animals of the O3/O2
group with complete remission of the auricular tumour were free of detectable lung
metastases on CT scans, which were performed after the end of the observation
period. Previous experiments with the VX2 auricle carcinoma found tumour cells
in pulmonary vessels 32 days after tumour induction without detection of solid
pulmonary metastases (32). Van Es et al. found lung metastases in 31% (5 of 16)
of rabbits that were sacrificed at different time points before day 28 after tumour
induction (89). A small metastasis was found in the lung of one rabbit that was
sacrificed 10 days after tumour induction. Early pulmonary metastases are often
due to seeding of the tumour cells at implantation (89). Thus, the presence of early
lung metastases in few rabbits during the O3/O2 sessions is possible, but it can be
expected that the majority of animals at that time point was free of lung metastases.
In summary, these observations indicate that the O3/O2 therapy is not only able to
prevent but also to clear lymph node and possibly distant metastases.
Interestingly, despite the fact that the ipsilateral parotid lymph node at autopsy
was enlarged in all O3/O2-treated animals that were not cured, only a relatively
small percentage of them (2 out of 8, 25.0%) compared with a high percentage of
sham treated animals (9 out of 13, 69.2%) also had macroscopically detectable lung
metastases. Since 90% of human cancer deaths are caused by distant metastases
it would be of high benefit, if O3/O2-PP could inhibit haematogeneous metastatic
spread of cancer cells (84). Whether this is really the case cannot be reliably an-
swered by our experiments, because we did not carry out a histologic evaluation of
enlarged parotid lymph nodes.
The insufflated O3/O2 gas mixture was composed of 97.5% oxygen and 2.5% ozone.
Therefore, we used a second control group of rabbits which received intraperitoneal
insufflations of pure oxygen. As expected, the insufflation of pure oxygen did not
significantly increase the 3-month survival probability and the complete remission
rate compared with sham treatment. Unlike our expectations, the difference of the
3-month survival probability and the complete remission rates between the O3/O2-
treated group and the O2-treated group was also not statistically significant. The
corresponding p-values however suggest that the insufflation of the medical O3/O2
gas mixture is more efficient than that of pure medical O2. The two tumours of




36) and 6.5 cm2 (day 24) and then decreased in size more slowly than those tumours
of the O3/O2-treated animals. Full remission was observed at day 68 and day 85
after tumour cell inoculation, which is by far later than the observed full remission
in O3/O2-treated animals. A possible explanation for these findings might be that
pure oxygen has some antitumourous effects, but only the combination with ozone is
potent enough to cause a statistically significant effect. Thus, the small O3 fraction
seems to be a crucial factor. In this context it might be of importance that the
mean tumour surface area A of the O2-treated animals was significantly smaller than
that of the two other groups during the treatment period. Many factors influence
the initial tumour growth, for example aggressiveness of tumour cells, quantity of
inoculated tumour cells and immune status of the host. The exact cause of this
observation in our experiment remains unclear.
5.2 Safety of the O3/O2 therapy
Since the O3/O2-PP method is a new therapeutic approach it is of high importance
to analyze possible adverse effects. The here used MedozonIP gas processor has an
integrated intraabdominal pressure control system (IAPC), which allows measure-
ment of the IAP during and after the insufflation process. Acute side effects due
to high IAP that might occur during the period of insufflation are unlikely, since
the measured peak pressure was below 5 mbar, classified as low IAP in laparoscopic
surgery (63).
Each insufflation process lasted approximately two to three minutes. Possible
acute hyperalgesic effects of the intraperitoneally insufflated O3/O2 gas mixture
could not be observed since the insufflation was performed in deep short narcosis.
Nevertheless it must be emphasized that Zorraquin et al. described acute pain reac-
tions after intraperitoneal insufflation of an O3/O2 gas mixture in humans when no
analgesics are given (101).The rabbits awoke from narcosis after six to eight minutes
and thereafter showed no detectable signs of pain.
We found a slight but significant reduction in body weight during and shortly after
the therapeutic treatment, which was a little more pronounced in the O3/O2-treated
group than in the O2-treated group. Similarly, a significant immediate weight loss up
to 14% was found in mice and rats after inhalation of ozone (54). One day after the
last treatment the mean body weight already began to increase, reaching its initial
value eleven days later. Thus, the body weight loss might represent a mild transient
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adverse effect. The observed transient weight loss could be the result of a decreased
food uptake, an influence on the fat metabolism or some unnoticed intraabdominal
pain reactions caused by the insufflated ozone and/or oxygen. Probably the O3/O2-
PP had no late adverse effects on the general health condition of NZW rabbits,
since the body weight of all cured rabbits constantly increased until the end of the
experiment.
The blood tests were unsuggestive of severe side effects of the O3/O2 therapy. A
mild leukocytosis, predominantly due to granulocytosis, was found one day after the
last treatment in all three treatment groups, but it was a little more pronounced in
the O3/O2 group. These results are in line with findings by Bette et al. who found an
increase in the number of circulating WBC (predominantly GRA and LYM) in rats
after repetitive O3/O2-PP (8). In cured animals WBC counts had fallen to normal
values prior to the end of the experiment. Thus, leukocytosis also was a transient
event after the O3/O2 gas insufflation. O3/O2-PP had no detectable effect on the
RBC count and on liver enzymes. Significantly increased CREA values on day 19
were still within the physiological range and possibly caused by hypovolaemia due
to decreased fluid intake. An effect on blood gas parameters could not be detected.
Clearly, the measurements cannot be used to describe very early occuring changes
of blood gas parameters after O3/O2 therapy, since they were performed not earlier
than 24 hours after the last gas insufflation. All measured blood parameters of cured
animals of the O3/O2 group were within the physiological range after the end of the
observation period.
Since ozone is toxic to the lungs in a concentration-dependent manner, one could
expect that ozone is also toxic to the membranes within the abdominal cavity (55).
However, at inspection of the abdominal cavity no abnormalities were detected.
Taken together, since no severe side effects such as sustained reduction in body
weight, gas embolism, fever, diarrhoea, peritonitis or obvious pain reactions were
observed, it appears that the O3/O2 therapy is relatively safe. Late adverse effects
of the O3/O2-PP are rather unlikely, since two rabbits from a previous pilot study
by Dr. S. Schulz (Veterinary Service and Laboratory Animal Medicine, Philipps
University Marburg, Germany) developed no clinical signs after more than 6 years
of tumour remission (data not shown).
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5.3 Former studies evaluating an effect of ozone on
cancer cells in vitro, in animal studies and in
humans
There are few studies that evaluate an effect of ozone on isolated cancer cells or
on cancers in animals and humans. Sachsenmaier et al. compared the effects of an
O3/O2 gas mixture and of X-rays on mouse ascites tumour cells in aqueous suspen-
sion (73). Depending on the exposure time and thus, on the ozone dosage, mouse
ascites tumour cells in suspension were destroyed and lost their tumour inducing
capacity, when they were brought in direct contact to the O3/O2 gas mixture. The
main attack point was the cell membrane. The effect of irradiation with X-rays had
only small similarity with the ozone effect. The destruction of the cell membrane
appeared much later and seemed to be less important. Intracellular effects seem to
play a key role in the cellular damage caused by X-rays. There is some evidence
from further in vitro studies that exposure to ozonated air can selectively inhibit
the proliferation of human cancer cells (87). Sweet et al. found a dose-dependent
growth inhibition of cancer cells of human lung adenocarcinoma, breast adenocar-
cinoma, uterine carcinosarcoma and endometrial carcinoma after incubation of the
cell cultures with ozonated ambient air at ozone concentrations of 0.3, 0.5 and 0.8
ppm for eight days, while the growth of human fibroblasts was not (0.3 and 0.5 ppm)
or only moderately inhibited (0.8 ppm) (87). These authors concluded that cancer
cells must be more sensitive to oxidative stress than normal cells. These results were
confirmed by Karlic et al. (50). They incubated human cancer cell cultures (in liq-
uid medium) of an ovarian adenocarcinoma and an endometrial adenocarcinoma and
human fibroblasts for two hours with an O3/O2 gas mixture at ozone concentrations
of 0.03, 0.1 and 0.3 ppm. Only the growth of the ovarian cancer cells was selectively
inhibited (at 0.03 ppm) or they were destroyed (at 0.1 and 0.3 ppm) after incuba-
tion with the O3/O2 gas mixture. Furthermore, they observed a possible additive
effect of ozone and ionizing radiation on tumour growth inhibition. Pre-incubation
of the endometrial cancer cells with the O3/O2 gas mixture at an ozone concentra-
tion of 0.1 ppm for 2 hours one week prior to irradiation with the gamma emitter
Ra226 resulted in growth inhibition of the tumour cells after irradiation, while expo-
sure to the O3/O2 gas mixture or irradiation alone had no inhibitory effect on the
growth of these cells. These authors concluded that ozone can selectively inhibit the
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growth of some cancer cells and that ozone must have radiosensitizing properties.
This issue was evaluated before by Grundner et al. (38). They incubated different
amounts of an O3/O2 gas mixture with an ozone concentration of 140 µg/ml with
Ehrlich-ascites cancer cells in an aqueous suspension. Irradiation with X-rays (2040
R) was performed directly before, during or after the ozone-incubation. In all three
situations, the exposure to the O3/O2 gas mixture had a dose-dependent negative
effect on the reproductive integrity of the cancer cells. Exposure to the O3/O2 gas
mixture after irradiation had a stronger inhibitory effect on the reproductive poten-
tial of mouse ascites tumour cells than ozone pre-treatment followed by irradiation.
These authors concluded that the co-operation of two mechanisms of which each
alone has toxic effects must have caused these results. Recently, Cannizzaro et al.
gave some insight in the mechanism by which ozone possibly causes inhibition of
cell growth or cell death in two human neuroblastoma cell lines.(23). In SK-N-SH
cells (human neuroblastoma cell line), they observed an arrest of the cells in the
G2-phase of the cell cycle, probably due to an inactivation of the cyclin B1/cdk1
complex which is critical for the cell cycle progression. In the SK-N-DZ cells (hu-
man neuroblastoma cell line) increased apoptosis via caspase 3 activation was found.
Furthermore, they found that exposure to an O3/O2 gas mixture combined with the
application of chemotherapeutic agents cisplatin and etoposide had an additive ef-
fect to chemotherapy resulting in stronger cell growth inhibition in vitro. Zänker
et al. had already demonstrated a synergistic effect of ozone and 5-fluorouracil on
human cancer cells in vitro. In this study 5-fluorouracil resistant human cancer cell
lines became susceptible to the chemotherapeutic agent after incubation with ozone
at a concentration of less than 1 ppm (102). These results from in vitro studies are
hardly comparable with the results of our study, since a direct contact of ozone and
the tumour cells is highly unlikely with our experimental design (as will be described
later).
Up to now, only few animal studies evaluating a possible antitumoural effect of
ozone exist. Grundner et al. carried out intravenous injections of a small amount
of an O3/O2 gas mixture in Naval Medical Research Institute (NMRI) albino mice
bearing Crocker-sarcoma 180 or Ehrlich-ascites tumour (39). After 5 intravenous
injections in a time period of 9 days (each time 0.05 ml O3/O2 gas mixture with an
ozone concentration of 140 µg/ml), there was a tendency towards a higher cure rate
in Crocker-sarcoma bearing mice but this was statistically not significant. There
also was a tendency towards higher cure rates in Crocker-sarcoma 180 bearing mice
54
Discussion
when the i.v. injections of the O3/O2 gas mixture were performed prior to or after
irradiation with X-rays compared with irradiation alone, but again this was statisti-
cally not significant. The Crocker-sarcomas of the animals treated with the O3/O2
gas mixture alone were significantly smaller than the tumours in control animals
one and seven days after the end of the treatment period. However, in a subsequent
experiment the results were not reproducible. Only a tendency towards (not statis-
tically significant) smaller tumour sizes was seen in animals receiving the O3/O2 gas
mixture injections after irradiation compared with animals that were only irradiated.
In the experiments with the Ehrlich-ascites tumour no effect of O3/O2 gas mixture
alone or with concomitant irradiation was observed. These authors concluded that
the lack of a clear antitumoural and radiosensitizing effect in these experiments
might be explained by the fact that the injected gas volume was very small. The
mice in these experiments received a single dosage of about 0.3 µg ozone/g body
weight (25 g body weight, 0.05 ml O3/O2 gas mixture per animal, 140 µg/ml ozone
concentration) while rabbits in our experiment received a single dosage of 4 µg
ozone/g body weight (80 ml/kg body weight O3/O2 gas mixture, ozone concentra-
tion 50 µg/ml). The same researchers conducted a consecutive animal experiment
in which they brought the O3/O2 gas mixture in direct contact to the tumour tissue
in vivo (40). NMRI mice bearing an intraperitoneal Ehrlich-ascites tumour were
treated with intraperitoneal injections of 3.0 ml of an O3/O2 gas mixture with an
ozone concentration of 140 µg/ml for 4 consecutive days. When the tumour take-
rate after transplantation of the ascites at the end of the treatment to other mice
was assessed, a small but statistically not significant delay of tumour growth was
noted. A further delay and a lower take-rate was observed, when these animals were
irradiated prior to insufflation of the O3/O2 gas mixture, but compared with the
corresponding control group it was not statistically significant. The greatest delay
and the lowest take-rate could be observed for tumour ascites of animals, that were
irradiated after the injection of the O3/O2 gas mixture, but there was no statistic
significance compared with the group receiving pure oxygen before the irradiation.
In another group of mice the tumour cells were implanted in a subcutaneous air bag
and 0.5 ml of an O3/O2 gas mixture with an ozone concentration of 140 µg/ml was
injected directly into the air bag daily on five consecutive days. When these tumours
grew they developed a small solid and a fluid phase. The amount of the produced
fluid was measured. Injection of the O3/O2 gas mixture reduced the amount of fluid
significantly compared with injection of pure oxygen. When the O3/O2 gas mixture
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was given after local irradiation, the fluid volume was reduced significantly com-
pared with animals receiving oxygen after irradiaton. A statistically non-significant
reduction in the measured fluid volume also was observed, when the O3/O2 gas
mixture was given prior to irradiation, compared with the animals in which oxygen
was given prior to irradiation. The results suggest a direct and radiosensitizing or
radiomimetic effect of the O3/O2 gas mixture, but the authors are cautious, since
the fluid volume produced by the solid tumour, that is free of tumour cells, is a
very imprecise measurement for the activity of the tumour cells. Again, these ob-
servations are hardly comparable to our study, since direct contact of ozone and the
cancer cells is highly unlikely to occur with our experimental design.
Controlled randomized clinical trials that demonstrate a clear antitumoural effect
of ozone therapy in human cancer patients do not exist. Two pilot studies by Clavo
et al. evaluated ozone therapy for human cancer treatment (26; 25). With the fact
in mind that tumour hypoxia is a relevant cause of radioresistance, they evaluated
the effect of ozone therapy on tumour oxygenation in patients with advanced head
and neck cancers (25). Patients were treated three times with the major AHT. A
volume of 200 ml fresh drawn whole blood was ex vivo exposed to an equal volume of
an O3/O2 gas mixture with an ozone concentration of 60 µg/ml and then reinfused
to the patient. The pO2 value was measured in metastatic lymph nodes. Inter-
estingly, metastatic lymph nodes which had initially the lowest pO2 value showed
the largest increase in oxygenation after the AHT sessions, while metastatic lymph
nodes with initially high pO2 values showed a decrease in oxygenation. The same
researchers also compared the effect of ozone therapy and concurrent radiotherapy
with chemoradiotherapy in patients with unresectable, locoregionally advanced and
in some patients distant metastatic head and neck cancers (26). Ozone therapy was
performed concurrently with radiotherapy, either with the above described tech-
nique of major AHT or by rectal insufflation of 300 ml of an O3/O2 gas mixture
with an ozone concentration of 60 µg/ml. The patients in the chemoradiotherapy
group received either induction chemotherapy with a combination of drugs (taxane,
platinum, 5-FU) or concurrent chemoradiotherapy with taxane. Despite the fact
that the patients in the ozone therapy group were significantly older and had more
advanced disease stages, the median overall survival in both groups was not sig-
nificantly different and there was even a tendency towards a longer median overall
survival in the group which received the ozone therapy concurrently to the radio-
therapy (8 months versus 6 months). These results indicate a possible additive effect
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of the ozone therapy in human patients with advanced cancer.
5.4 Considerations on the effects of ozone therapy in
general and possible antitumoural effects in
particular
Ozone is a highly reactive oxidant gas, that reacts immediately when it comes in
contact with biomolecules. The primary target molecules for ozone in biological
systems are UFA, antioxidants like ascorbic and uric acid, thiol compounds like the
amino acid cysteine, GSH, albumin, carbohydrates, enzymes, DNA and RNA (15).
Pryor et al. have discussed a cascade mechanism for the toxic action of ozone.
They proposed that the reaction of ozone with primary target molecules produces
secondary more stable products that react with secondary targets to produce tertiary
products, and so on (67). In this view, the reaction of ozone with (P)UFA as primary
target molecules in the lung lining fluid, the blood plasma or the cell membranes is
central. The net reaction in the presence of water (reflecting the situation in human
blood plasma, lung lining fluid, urine and so on) is given by
R-CH=CH-R
′
+ O3 + H2O −→ R-CH=O + R′-CH=O + H2O2 .
Thus, the reaction of one mole of (P)UFA with one mole of ozone formally leads
to the formation of two moles of aldehydes (R-CH=O) and one mole of hydrogen
peroxide (H2O2) (68). Other peroxidic substances like the Crigee ozonides and
hydroxy hydroperoxides are only formed in very small amounts (less than 5%) under
these conditions (68). Regarding the proposed cascade mechanism of ozone action,
aldehydes and hydrogen peroxide are the secondary products that may react with
secondary targets.
It is well known that surface-active phospholipid (SAPL) lines the peritoneum,
providing a slippery and non-adhesive surface for smooth movement of the ab-
dominal organs. Phosphatidylcholine (PC) is the major SAPL. Interestingly, the
PC profile of the peritoneal surfactant is different from that of the pulmonary
surfactant in humans and rats (24; 36). In the peritoneal surfactant of humans
only unsaturated phosphatidylcholine (USPC) was found (e.g. palmitoyl-linoleoyl-
phosphatidylcholine (PLPC), palmitoyl-oleoyl-phosphatidylcholine (POPC)). USPC
means that the PC contains one or two UFA. In contrast, the major PC of the pul-
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monary surfactant is a saturated phosphatidylcholine (SPC) containing no UFA.
Regarding the high reactivity of ozone with UFA and PUFA, these USPC species
which are among the first biomolecules that come into contact with the intraperi-
toneally insufflated ozone, are probably the main primary target molecules that
ozone reacts with.
Pryor discussed the issue, how far ozone can penetrate into tissues without being
consumed by reactive absorption (67). He used a calculational method (the Einstein-
Smoluchowski equation) to estimate the amount of ozone that could pass through
a lipid bilayer or the lung lining fluid layer (mucus and surfactant). According to
his calculations, little or none of the ozone would penetrate the lung lining fluid
layer without reacting with target molecules in this lung lining fluid layer (GSH,
ascorbate, uric acid, UFA). This model leads to similar results, when applied for the
ozone passage through a lipid bilayer. Only a small part or none of the ozone would
reach the cytoplasm, a substantial fraction ore all of the ozone would react with
target molecules (UFA, thiols, tocopherol) in the bilayer. Transport of free ozone
via the blood route and thus, the generation of reactive oxygen species (ROS) by
free ozone at the distant tumour site appears not likely. Therefore, LOPs originated
from the reaction of ozone with biomolecules at the peritoneal surface are most
likely the messengers responsible for triggering the observed antitumoural effect in
the VX2 model. Bocci, who extensively studied the effect of exposure of human
whole blood ex vivo to an ozone/oxygen gas mixture, states that the major ozone
messengers can be divided into two groups. On the one hand, immediately and
short-acting messengers called ROS (including hydrogen peroxide) and on the other
hand late and long-lasting messengers called LOPs (including aldehydes) (15). While
the ROS have a lifetime of less than one second and cannot be transported via the
blood route to distant sites, the half-life of LOPs is much longer and distribution
to distant tissues is possible. Therefore, it is logical to regard more detailed what is
known about biological effects of ROS (hydrogen peroxide) and LOPs (aldehydes).
H2O2 is well known as an inter- and intracellular signaling molecule (41). When
produced extracellular from the ozonolysis of PUFA, H2O2 can easily diffuse into the
cytoplasm of cells. H2O2 was found as a messenger in the activation of transcription
factor NFκB in Jurkat T-cells (77). Activated NFκB moves to the nucleus and is able
to switch on genes for cytokine production. The activation of NFκB via the second
messenger H2O2 was proven for some other cell types (murine fibroblasts, pre-B cells,
HeLa cells), but this effect seems to be cell-specific, since many cells have proven
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insensitive to H2O2 mediated NFκB activation (including monocytes, astrocytoma
cells, J. Jahn lymphoblastoid T cells, KB epidermal cells) (18). Bocci and colleagues
found an induction of interferon gamma, TNF-α, transforming growth factor-β, IL-
2 and IL-8 after in vitro incubation of human blood or human mononuclear cells
with ozone (12; 10; 11; 14; 13; 15; 65). Thus, activation or modulation of the
immune system via the second messenger H2O2 may be a mechanism of the effect
of ozone therapy. Interstingly, O3/O2-PP exhibited potent protective effects on
polymicrobial-induced lethal sepsis in rats, probably by altering the immune status
(79).
Pryor et al. have studied the biological effects of LOPs, mainly in an attempt to
clear the toxic pulmonary effects of ozone inhalation (69). Former in vitro studies
suggested a dose-dependent increase of phospholipase (PLA2, PLC, PLD) activity
in guinea pig tracheal epithelial cells after incubation with ozone (99). Incubation of
a human bronchial epithelial cells with HHP-C7 (the hydroxyhydroperoxide formed
from the ozonation of palmitoleic acid) resulted in increased arachidonic acid re-
lease due to activation of PLA2 (69). In a consecutive study, Kafoury et al. could
show that exposure of human bronchial epithelial cells in culture to 1-palmitoyl-2-
(9-oxononanoyl)-sn-glycero-3-phosphocholine (PC-ALD), a specicifc PLA2 stimula-
tory LOP, significantly increased the release of platelet-activating factor (PAF) and
prostaglandin E2 (PGE2) and exposure to 1-hydroxy-1-hydroperoxynonane (HHP-
C9), a specific PLC stimulatory LOP, significantly increased the release of IL-6, IL-8
and PAF (49). These authors concluded that LOP-dependent release of proinflam-
matory mediators may play an important role in the early inflammatory response
seen during exposure to ozone.
LOPs can furthermore elicit an upregulation of endogenous antioxidants, such as
glutathion or superoxid dismutase (66). LOPs were also shown to induce oxidative
stress proteins like haeme-oxygenase 1, which after activation degrades haemoglobin
leading to the formation of the potent antioxidant bilirubin (9). It is therefore
believed that ozone therapy, as an acute oxidative stress, is capable of inducing
endogenous antioxidant responses, which help to overcome chronic oxidative stresses
to which the human body is often exposed (15).
We could show that rabbits with complete remission of the VX2 tumour after
O3/O2 therapy were resistant to reinoculation of the VX2 tumour cell suspension
into both auricles. This observation points to an involvement of the immune sys-
tem in tumour clearance, particularly the adaptive immune system. The loss of
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tolerance against reimplantation of VX2 tumours after immune suppression sup-
ports this hypothesis. Van Es et al. already showed that stimulation of the immune
system with the immune modulating agent IL-2 resulted in regression of the auric-
ular VX2 tumours in rabbits, although at a lower efficiency (25.0%) than found in
the O3/O2-PP group (42.9%) (88). Numerous effector cells from the adaptive and
from the innate immune system might be responsible for tumour regression. In an
animal model with a mice strain that exhibits spontaneous regression/complete re-
sistance (SR/CR) to multiple transplantable cancer cell lines, leukocytes infiltrating
the tumour site consisted of a mixture of multiple subsets of effector cells composed
primarily of macrophages, polymorphonuclear cells, NK cells and cytotoxic T lym-
phocytes (28; 44). Depletion or transfer of specific leukocyte populations of the
adaptive or the innate immune system showed, that primarily the innate immune
system is involved in successful tumour regression and complete resistance against
reimplantation of the tumours in SR/CR mice. Each leukocyte subpopulation ex-
hibits individual tumour cell killing mechanisms by the secretion of different effector
molecules such as perforins, granzymes and ROS. In SR/CR mouse model the re-
lease of ROS by macrophages was identified as one major effector mechanism of
the anticancer immune response (45). Therefore, production of ROS by activated
macrophages and/or granulocytes could be a possible mechanism of anticancer ef-
fects induced by the insufflation of O3/O2 gas mixture in our study. In this context,
the observed mild leukocytosis including granulocytosis after the therapeutical ses-
sions with O3/O2 might represent activated leukocytes as potent anticancer effector
cells also in the VX2 model.
Assuming that the hypothesis of leukocyte activation as the key antitumoural
effect of O3/O2-PP is true, the next question would be where this activation takes
place. On the one hand it seems to be possible that leukocytes are activated within
the peritoneal cavity or the peritoneum and that these activated leukocytes or prod-
ucts of activated leukocytes are distributed via the circulation. On the other hand
it might be possible that ozone reaction products, most likely the LOPs, are dis-
tributed via the circulation and that leukocyte activation takes place at sites distant
from the peritoneum. The peritoneum is mainly protected by the innate immune
system, the adaptive immune system is said to function as a secondary amplifica-
tion system (43). The greater omentum harbours the so-called “milky spots”, which
probably play a key role in the immunity of the peritoneum (27). The milky spots
in humans and laboratory animals are accumulations of leukocytes. Macrophages
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represent the major cell type, followed by B-lymphocytes, T-lymphocytes and to
a small percent mast cells (81). Activated macrophages migrate from the omental
milky spots into the peritoneal cavity, a process which is mediated by the expression
of cell adhesion molecules (27; 80). Interestingly, the intraperitoneal administration
of granulocyte/macrophage-colony-stimulating factor (GM-CSF) increased the tu-
mouricidal activity of milky spot macrophages against intraperitoneal tumours in
rats (53).
Intraperitoneally insufflated ozone might also react on the arachidonic acid meta-
bolism in the mesothelium, consisting of different mesothelial cell types, which is
reminiscent to the situation in the eicosanoid metabolism of human airway epithelial
cells after exposure to ozone (58). Several components of the prostanoid biosynthesis
pathway were found to exhibit oncolytic and antimetastatic effects on tumour cells
and tumour progression (46; 76). Encouraging studies are currently under way to
analyze changes in the plasma levels of different arachidonic acid metabolites during
the course of O3/O2 insufflation in rabbits.
5.5 Ozone therapy and HNSCC
As is true for many cancers, HNSCC tumour cells somehow evade the body’s immune
system. Many mechanisms have been identified that contribute to the diminished
immune surveillance of HNSCC tumour cells (100; 47). By the production of immune
inhibitory factors cancer cells directly suppress the immune reaction of the host.
Immune inhibitory factors that were found to be produced by HNSCC are PGE2,
TGFβ, IL-6 and IL-10 (100). In addition, induction and mobilisation of immune
inhibitory CD34+ cells and blockade of dendritic cell maturation were observed in
patients with HNSCC (47). Tumours not only suppress the immune system of the
host, they also have developed mechanisms for immune escape. This can partly
be explained by the frequently observed downregulation or loss of MHC class I
determinants (96; 61). Therefore, being able to activate the immune surveillance
capacity is an emerging concept in recent cancer immunotherapies, particularly those
focusing on immunomodulators or upregulators of the immune response (62; 86;
97). To augment the host’s immune response against cancer cells, therapies with
recombinant cytokines, dendritic cell immunization and tumour antigen vaccination
as well as T cell-based immunotherapies are currently under investigation (100;
47). In this context, the intraperitoneal O3/O2 gas mixture therapy seems to be a
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promising new tool in cancer treatment.
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6 Summary
About 6% of all newly diagnosed malignancies worldwide are cancers of the head
and neck. They account for nearly 5% of all cancer-related deaths. Surgery, radia-
tion therapy and chemotherapy as well as combinations of these three are currently
regarded as the standard treatment. While high cure rates can be achieved for the
early stage disease, cure and survival rates for locoregionally advanced and distant
metastatic disease are still disappointing. Thus, the development of new treatment
strategies is essential, particularly for the treatment of cancers with metastatic in-
volvement of the lymph nodes.
The VX2 auricle carcinoma of New Zealand White rabbits (NZWR) is an accepted
animal model for human head and neck cancers, since both are similar in growth
leading to early regional lymph node metastases and subsequent distant metastatic
spread. Ozone, 2002 recognized as a biomolecule since it was found to be endoge-
nously produced by human neutrophils, exhibited protective effects in a rat sepsis
model when insufflated intraperitoneally as a gas mixture with oxygen. This find-
ing suggests that ozone might have immunemodulatory properties. In vitro, ozone
was found to inhibit selectively the growth of human cancer cells. However, until
now there are no randomized controlled trials that show a clear therapeutic effect
of ozone on cancer disease.
The aim of this study was to test the effects of an intraperitoneally insufflated
O3/O2 gas mixture (O3/O2-pneumoperitoneum, O3/O2-PP) on growth of the pri-
mary tumour and metastatic spread of the VX2 auricle cancer in NZWR. Fourteen
days after inoculation of a VX2 tumour cell suspension into the subcutis of the
right auricle rabbits were randomized to three experimental groups. The treatment
was performed daily for five consecutive days, beginning on day 14 after tumour
cell inoculation. Rabbits in Group A (n = 14, O3/O2 group) each day received
an intraperitoneally insufflated volume of 80 ml/kg body weight of an O3/O2 gas
mixture with an ozone concentration of 50 µg/ml gas mixture. Rabbits in Group B
(n = 13, O2 group) received the same amount of pure oxygen and rabbits in Group
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C (n = 14, Sham group) were sham-treated. Arterial blood samples were taken on
day 14 (prior to initiation of treatment) and on day 19 (after the last treatment) and
standard haematological and clinical chemistry blood parameters were measured.
O3/O2-PP significantly increased the 3-month survival probability (50.0%) and
the complete remission rate (42.9%) compared with sham treatment (7.1% 3-month
survival probability and complete remission rate). The 3-month survival probabil-
ity (23.1%) and complete remission rate (15.4%) of the rabbits that received pure
medical oxygen were neither significantly different from the sham group nor from the
O3/O2 group. All animals with complete remission of the primary tumour had an
enlarged sentinel lymph node (parotid lymph node) at the beginning of the treat-
ment period that regressed simultaneously. None of these rabbits had detectable
lung metastases at day 90 on computed tomography scans of the thorax. No severe
side effects could be detected except for a mild transient body weight loss and a
mild leukocytosis pointing to O3/O2-PP as a relatively safe method. Animals of the
O3/O2 group with complete tumour remission were resistant to the tumour cells after
reinoculation of the tumour cell suspension. However, when treating these animals
with dexamethasone and cyclosporin A, rabbits became susceptible to reinoculation
of the tumour again. This indicates a crucial role of the immune system in tumour
eradication with subsequent resistance to reimplantation.
However, prior to a potential clinical use of the O3/O2-PP method, further re-
search is essential to clear up the exact mechanisms by which ozone exerts this
antitumoural effects. Particularly, further clarification is needed regarding the dose-
response relationship, evaluation of yet undetected adverse effects and reproducibil-
ity of the results of the VX2 tumour model in other tumour model systems.
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7 Zusammenfassung
Weltweit machen bösartige Tumoren des Kopf-Hals-Bereichs etwa 6% aller Krebs-
neuerkrankungen aus, mit einem Anteil an den Krebssterbefällen von circa 5%. Ope-
ration, Radiotherapie und Chemotherapie sowie deren Kombinationen gelten heute
als anerkannte Therapieverfahren. Während bei lokal und regional begrenzten Tu-
moren hohe Heilungsraten erzielt werden, sind die Heilungs- und Überlebensraten
beim Vorliegen von Lymphknoten- und Fernmetastasen nach wie vor deutlich ge-
ringer. Die Entwicklung neuer Therapieverfahren, insbesondere zur Therapie von
bereits metastasierten Tumoren, ist deshalb unbedingt notwendig.
Das aurikuläre VX2-Karzinom beim weißen Neuseelandkaninchen ist ein akzep-
tiertes Tumormodell für humane neoplastische Erkrankungen des Kopf- und Hals-
bereichs, da es in seinem Wachstumsverhalten mit früher lymphogener und im fort-
geschrittenen Krankheitsverlauf auftretender Fernmetastasierung große Ähnlichkeit
zu den beim Menschen vorkommenden Kopf-Hals-Tumoren aufweist. Ozon, welches
2002 auch als endogen von neutrophilen Granulozyten gebildetes Biomolekül ent-
deckt wurde, zeigte bei intraperitonealer Applikation als Gasgemisch mit Sauerstoff
einen protektiven Effekt im Sepsismodell der Ratte, was auf einen bereits zuvor pos-
tulierten immunmodulatorischen Effekt hindeutet. In vitro hemmte Ozon selektiv
das Wachstum von Zellkulturen humaner Karzinome, jedoch gab es bisher keine
randomisierten kontrollierten Studien mit ausreichend großen Fallzahlen, die einen
klaren therapeutischen Effekt von Ozon bei Krebserkrankungen zeigen konnten.
Es war daher das Ziel dieser Studie, den Effekt eines intraperitoneal applizierten
Ozon-Sauerstoff-Gasgemischs (O3/O2-Pneumoperitoneum, O3/O2-PP) auf die Pri-
märtumorentwicklung und Metastasierung des VX2-Karzinoms beim weißen Neusee-
landkaninchen zu untersuchen. Dazu wurden die Kaninchen 14 Tage nach subku-
taner Inokulation einer VX2 Tumorzellsuspension in das rechte Ohr randomisiert
drei Versuchsgruppen zugeordnet. Die Behandlung, beginnend am Tag 14 nach
Tumorzellinokulation, wurde täglich an fünf aufeinander folgenden Tagen durchge-
führt. Den Kaninchen in Gruppe A (n = 14, O3/O2 Gruppe) wurden pro Be-
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handlung 80 ml/kg Körpergewicht eines Ozon-Sauerstoff-Gasgemischs mit einer
Ozonkonzentration von 50 µg/ml Gas intraperitoneal insuffliert, den Kaninchen in
Gruppe B (n = 13, O2 Gruppe) dieselbe Menge puren Sauerstoffs. Die Kaninchen
in Gruppe C (n = 14, Sham Gruppe) erhielten eine Sham-Behandlung. Arterielle
Blutproben wurden am Tag 14 (vor Behandlung) und am Tag 19 (nach Behandlung)
entnommen und auf hämatologische und klinisch-chemische Standardparameter un-
tersucht.
Die Behandlung mittels O3/O2-PP erhöhte signifikant die 3-Monats-Überlebens-
rate (50.0%) und die komplette Remissionsrate (42.9%) der behandelten Tiere ver-
glichen mit der Sham-Behandlung (7.1% 3-Monats-Überlebensrate und komplette
Remissionsrate). Die 3-Monats-Überlebensrate (23.1%) und die komplette Remis-
sionsrate (15.4%) der mit purem Sauerstoff behandelten Tiere war weder gegenüber
der Sham Gruppe noch gegenüber der O3/O2 Gruppe signifikant unterschiedlich.
Alle Tiere mit kompletter Remission des Primärtumors zeigten parallel auch eine Re-
mission des zum Zeitpunkt der Therapie vergrößert tastbaren Wächterlymphknotens
(Parotislymphknoten). Bei diesen Tieren wurden bei einer Computertomographie
des Thorax am Tag 90 keine Lungenmetastasen gefunden. Abgesehen von einem
leichten transienten Gewichtsverlust und einer milden Leukozytose konnten keine
wesentlichen Nebenwirkungen gefunden werden. Daher scheint die Behandlung mit-
tels O3/O2-PP eine relativ sichere Methode zu sein. Die Tiere aus der O3/O2 Gruppe
mit kompletter Tumorremission zeigten sich bei Reinokulation der Tumorzellsus-
pension resistent gegen die Tumorzellen. Durch Suppression des Immunsystems
mit Dexamethason und Ciclosporin A konnte die Resistenz jedoch durchbrochen
werden und die Kaninchen entwickelten wieder Tumoren nach Reinokulation der
Tumorzellsuspension. Dies deutet auf eine wichtige Rolle des Immunsystems bei
der Tumoreradikation mit nachfolgender Resistenz hin.
Bevor die O3/O2-PP Methode eines Tages vielleicht beim Menschen eingesetzt
werden kann, ist zunächst eine weiterführende Forschung notwendig um den exakten
Mechanismus der beobachteten Ozonwirkungen zu klären. Im Speziellen sollte eine
Dosis-Wirkungs-Beziehung erstellt, nach bislang nicht entdeckten Nebenwirkungen
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DMEM Dulbecco’s Modified Eagle Medium
EGFR Epidermal growth factor receptor
EDTA Ethylenediaminetetraacetic acid
G-BA Gemeinsamer Bundesausschuss der Ärzte und Krankenkassen
GOT Glutamic oxaloacetic transaminase





HNC Head and neck cancer
HNSCC Head and neck squamous cell carcinoma
IAPC Intraabdominal Pressure Control
IL Interleukin
LOP Lipid ozonation (oxidation) product
LYM Lymphocytes
MO Monocytes
NMRI Naval Medical Research Institute
ns not significant






(P)UFA (Poly)unsaturated fatty acid
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RBC Red blood cells
ROS Reactive oxygen species
SAPL Surface-active phospholipid
SPC Saturated phosphatidylcholine
TTC Time to tumour clearance
USPC Unsaturated phosphatidylcholine
WBC White blood cells
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zur Durchführung dieser Arbeit, sowie für seine Unterstützung des gesamten Pro-
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Weiterer Dank gilt Herrn Prof. Dr. R. Nüsing und Herrn Ludwig für die Bereit-
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